pmcid,outcome,intervention,comparator,outcome_type,intervention_events,intervention_group_size,comparator_events,comparator_group_size,intervention_mean,intervention_standard_deviation,comparator_mean,comparator_standard_deviation,intervention_rate,comparator_rate,source_file
115849,Discontinuation due to lack of efficacy,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,binary,44.0,353.0,19.0,181.0,,,,,,,115849_zeroshot.jsonl
115849,Patient global assessment of disease activity,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,66.0,20.0,65.0,19.0,,,115849_zeroshot.jsonl
115849,investigator global assessment of disease activity,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,2.7,0.7,2.7,0.6,,,115849_zeroshot.jsonl
115849,Tender joint count,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,29.0,15.0,29.0,15.0,,,115849_zeroshot.jsonl
115849,Swollen joint count,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,19.0,13.0,19.0,12.0,,,115849_zeroshot.jsonl
115849,Patient global assessment of pain,etoricoxib 90 mg once daily,placebo,continuous,,,,,,,,,,,115849_zeroshot.jsonl
115849,Health Assessment Questionnaire disability,etoricoxib 90 mg once daily,placebo,continuous,,,,,,,,,,,115849_zeroshot.jsonl
115849,Serum C-reactive protein,etoricoxib 90 mg once daily,placebo,continuous,,,,,,,,,,,115849_zeroshot.jsonl
115849,ACR20 responder criteria,etoricoxib 90 mg once daily,placebo,binary,207.0,353.0,146.0,357.0,,,,,,,115849_zeroshot.jsonl
115849,Discontinuation due to lack of efficacy,etoricoxib 90 mg once daily,placebo,binary,44.0,353.0,90.0,357.0,,,,,,,115849_zeroshot.jsonl
115849,Patient global assessment of disease activity,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,65.0,19.0,65.0,19.0,,,115849_zeroshot.jsonl
115849,investigator global assessment of disease activity,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,2.7,0.6,2.7,0.6,,,115849_zeroshot.jsonl
115849,Tender joint count,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,28.0,15.0,29.0,15.0,,,115849_zeroshot.jsonl
115849,Swollen joint count,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,18.0,12.0,19.0,12.0,,,115849_zeroshot.jsonl
115849,Patient global assessment of pain,naproxen 500 mg twice daily,placebo,continuous,,,,,,,,,,,115849_zeroshot.jsonl
115849,Health Assessment Questionnaire disability,naproxen 500 mg twice daily,placebo,continuous,,,,,,,,,,,115849_zeroshot.jsonl
115849,Serum C-reactive protein,naproxen 500 mg twice daily,placebo,continuous,,,,,,,,,,,115849_zeroshot.jsonl
115849,ACR20 responder criteria,naproxen 500 mg twice daily,placebo,binary,104.0,181.0,146.0,357.0,,,,,,,115849_zeroshot.jsonl
115849,Discontinuation due to lack of efficacy,naproxen 500 mg twice daily,placebo,binary,19.0,181.0,90.0,357.0,,,,,,,115849_zeroshot.jsonl
115849,Patient global assessment of disease activity,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,66.0,20.0,65.0,19.0,,,115849_zeroshot.jsonl
115849,investigator global assessment of disease activity,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,2.7,0.7,2.7,0.6,,,115849_zeroshot.jsonl
115849,Tender joint count,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,29.0,15.0,28.0,15.0,,,115849_zeroshot.jsonl
115849,Swollen joint count,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,19.0,13.0,18.0,12.0,,,115849_zeroshot.jsonl
115849,Patient global assessment of pain,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,,,,,,,,,,115849_zeroshot.jsonl
115849,Health Assessment Questionnaire disability,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,,,,,,,,,,115849_zeroshot.jsonl
115849,Serum C-reactive protein,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,,,,,,,,,,115849_zeroshot.jsonl
115849,ACR20 responder criteria,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,binary,207.0,353.0,104.0,181.0,,,,,,,115849_zeroshot.jsonl
115849,patients discontinued due to lack of efficacy,etoricoxib 90 mg once daily,placebo,binary,44.0,353.0,90.0,357.0,,,,,,,115849_zeroshot.jsonl
115849,patients discontinued due to lack of efficacy,naproxen 500 mg twice daily,placebo,binary,19.0,181.0,90.0,357.0,,,,,,,115849_zeroshot.jsonl
1216327,The mean body weight gain,White Grape Juice (WGJ),colored and flavored water (WA),continuous,,30.0,,30.0,50.6,,-7.0,,,,1216327_zeroshot.jsonl
1216327,The duration of the illness,White Grape Juice (WGJ),colored and flavored water (WA),continuous,,30.0,,30.0,47.5,38.9,26.5,27.4,,,1216327_zeroshot.jsonl
1216327,The fecal losses,White Grape Juice (WGJ),colored and flavored water (WA),continuous,,30.0,,30.0,3.59,2.35,2.19,1.63,,,1216327_zeroshot.jsonl
1475568,Minnesota living with heart failure (MLHF) questionnaire baseline scores,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59.0,,64.0,45.0,,57.0,,,,1475568_zeroshot.jsonl
1475568,Heart failure-related quality of life at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,,,,,,,,,,1475568_zeroshot.jsonl
1475568,Baseline hypertension,Follow-up and thorough education on self-care,Standard information about self-care,binary,51.0,59.0,57.0,64.0,,,,,,,1475568_zeroshot.jsonl
1475568,Baseline diabetes,Follow-up and thorough education on self-care,Standard information about self-care,binary,35.0,59.0,33.0,64.0,,,,,,,1475568_zeroshot.jsonl
1475568,Baseline life-quality score,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59.0,,64.0,45.0,,57.0,,,,1475568_zeroshot.jsonl
1475568,Knowledge about heart failure,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59.0,,64.0,55.0,,57.0,,,,1475568_zeroshot.jsonl
1475568,Baseline beta-blockers intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,32.0,59.0,46.0,64.0,,,,,,,1475568_zeroshot.jsonl
1475568,Self-efficacy,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59.0,,64.0,22.0,,22.0,,,,1475568_zeroshot.jsonl
1475568,Baseline systolic dysfunction,Follow-up and thorough education on self-care,Standard information about self-care,binary,23.0,59.0,28.0,64.0,,,,,,,1475568_zeroshot.jsonl
1475568,Baseline angiotensin II receptor blockers (ARBs) intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,,,,,,,,,,,1475568_zeroshot.jsonl
1475568,Baseline digoxin intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,15.0,59.0,12.0,64.0,,,,,,,1475568_zeroshot.jsonl
1475568,Baseline angiotensin-converting enzyme (ACE) inhibitors intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,,,,,,,,,,,1475568_zeroshot.jsonl
1475568,Hospitalization or death,Follow-up and thorough education on self-care,Standard information about self-care,binary,25.0,59.0,39.0,64.0,,,,,,,1475568_zeroshot.jsonl
1475568,Daily weight monitoring at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,binary,47.0,59.0,19.0,64.0,,,,,,,1475568_zeroshot.jsonl
1475568,Cardiac-related hospitalization,Follow-up and thorough education on self-care,Standard information about self-care,binary,20.0,59.0,25.0,64.0,,,,,,,1475568_zeroshot.jsonl
1574360,The amount of saturated fat in the foods purchased,fully automated advice that recommended specific switches from selected products higher in saturated fat to alternate similar products lower in saturated fat,control received general non-specific advice about how to eat a diet lower in saturated fat,continuous,,246.0,,251.0,0.77,,0.04,,,,1574360_zeroshot.jsonl
1574360,the average cost of the food,fully automated advice that recommended specific switches from selected products higher in saturated fat to alternate similar products lower in saturated fat,control received general non-specific advice about how to eat a diet lower in saturated fat,continuous,,,,,0.63,,0.62,,,,1574360_zeroshot.jsonl
1863515,haemoglobin level between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,continuous,,769.0,,667.0,10.7,,11.2,,,,1863515_zeroshot.jsonl
1863515,leucocyte count between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,continuous,,769.0,,667.0,8818.0,,8362.0,,,,1863515_zeroshot.jsonl
1863515,absolute neutrophil count between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,continuous,,769.0,,667.0,5639.0,,6150.0,,,,1863515_zeroshot.jsonl
1863515,haemoglobin level at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,continuous,,739.0,,638.0,10.7,,11.2,,,,1863515_zeroshot.jsonl
1863515,leucocyte count at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,continuous,,739.0,,632.0,8818.0,,8362.0,,,,1863515_zeroshot.jsonl
1863515,absolute neutrophil count at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,continuous,,739.0,,632.0,5639.0,,6150.0,,,,1863515_zeroshot.jsonl
2363753,Days with fever,Amifostine,Control,continuous,,20.0,,20.0,2.0,,4.0,,,,2363753_zeroshot.jsonl
2363753,Hospital stay,Amifostine,Control,continuous,,20.0,,20.0,16.0,,18.0,,,,2363753_zeroshot.jsonl
2363753,Grade III/IV stomatitis,Amifostine,Control,binary,5.0,20.0,10.0,20.0,,,,,,,2363753_zeroshot.jsonl
2363753,Glomerular filtration rate fall,Amifostine,Control,continuous,,20.0,,20.0,10.0,,37.0,,,,2363753_zeroshot.jsonl
2430617,HBeAg sero-conversion rate,60 µg of immune complexes (YIC),placebo,binary,17.0,78.0,7.0,78.0,,,,,,,2430617_zeroshot.jsonl
2430617,adverse events,30 µg YIC,placebo,binary,76.0,83.0,69.0,79.0,,,,,,,2430617_zeroshot.jsonl
2430617,adverse events,60 µg of YIC,placebo,binary,74.0,80.0,69.0,79.0,,,,,,,2430617_zeroshot.jsonl
2596788,GERD-knowledge,education,control,continuous,,102.0,,109.0,17.0,,13.4,,,,2596788_zeroshot.jsonl
2667135,proportion of patients completed therapy,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,93.0,103.0,44.0,97.0,,,,,,,2667135_zeroshot.jsonl
2667135,early discontinuations,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,10.0,103.0,53.0,97.0,,,,,,,2667135_zeroshot.jsonl
2667135,rate of clinical success at the test-of-cure visit,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,89.0,103.0,54.0,97.0,,,,,,,2667135_zeroshot.jsonl
2667135,deaths,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,4.0,103.0,18.0,97.0,,,,,,,2667135_zeroshot.jsonl
2681019,Adiponectin in women,Red wine,Control,continuous,,24.0,,24.0,29.8,,0.0,,,,2681019_zeroshot.jsonl
2681019,Adiponectin in men,Ethanol solution,Control,continuous,,24.0,,24.0,17.4,,0.0,,,,2681019_zeroshot.jsonl
2681019,Adiponectin in men,Beer,Control,continuous,,24.0,,24.0,16.1,,0.0,,,,2681019_zeroshot.jsonl
2836833,Fecal fat loss,1500 mg calcium,500 mg calcium,continuous,,34.0,,34.0,10.35,1.8,7.35,1.75,,,2836833_zeroshot.jsonl
2836833,weight loss,1500 mg calcium,500 mg calcium,continuous,,,,,,,,,,,2836833_zeroshot.jsonl
2836833,systolic or diastolic blood pressure,1500 mg calcium,500 mg calcium,continuous,,,,,,,,,,,2836833_zeroshot.jsonl
2836833,Urinary calcium excretion,1500 mg calcium,500 mg calcium,continuous,,34.0,,34.0,146.4,77.9,128.3,57.9,,,2836833_zeroshot.jsonl
2952311,Verbal rating scale pain intensity,Acupressure at distal points,Control,continuous,,11.0,,11.0,1.7,0.8,1.8,0.6,,,2952311_zeroshot.jsonl
2952311,Verbal rating scale pain intensity,Acupressure at local points,Control,continuous,,11.0,,11.0,2.1,0.5,1.8,0.6,,,2952311_zeroshot.jsonl
2952311,State-Trait Anxiety Inventory-I,Acupressure at local points,Control,continuous,,11.0,,11.0,44.5,8.0,39.2,9.5,,,2952311_zeroshot.jsonl
2952311,Salivary alpha-amylase,Acupressure at distal points,Acupressure at local points,continuous,,11.0,,11.0,36.8,27.9,20.0,9.0,,,2952311_zeroshot.jsonl
2952311,Muscle hardness,Acupressure at local points,Control,continuous,,11.0,,11.0,57.4,4.5,56.9,5.0,,,2952311_zeroshot.jsonl
2952311,State-Trait Anxiety Inventory-I,Acupressure at distal points,Control,continuous,,11.0,,11.0,43.2,6.8,39.2,9.5,,,2952311_zeroshot.jsonl
2972614,Adverse effects,Laser therapy (Group I),Placebo laser therapy (Group II),binary,0.0,30.0,0.0,22.0,,,,,,,2972614_zeroshot.jsonl
2972614,Severity of pain,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,3.76,1.45,4.63,2.1,,,2972614_zeroshot.jsonl
2972614,Shoulder Pain and Disability Index score,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,44.33,2.8,36.39,20.53,,,2972614_zeroshot.jsonl
2972614,Laboratory parameters,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,,,,,,,,,,2972614_zeroshot.jsonl
2972614,Motion range - Shoulder flexion,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,168.0,22.65,174.31,14.98,,,2972614_zeroshot.jsonl
2972614,Motion range - Shoulder extension,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,42.66,3.4,42.95,3.98,,,2972614_zeroshot.jsonl
2972614,Motion range - Shoulder abduction,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,166.66,21.38,172.72,16.67,,,2972614_zeroshot.jsonl
2972614,Motion range - Shoulder adduction,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,42.0,4.27,42.04,5.26,,,2972614_zeroshot.jsonl
2972614,Motion range - Shoulder internal rotation,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,49.33,9.62,49.77,4.49,,,2972614_zeroshot.jsonl
2972614,Motion range - Shoulder external rotation,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,44.83,5.64,44.09,1.97,,,2972614_zeroshot.jsonl
2974815,discontinued treatment,phone calls group,no phone calls group,binary,4.0,108.0,30.0,246.0,,,,,,,2974815_zeroshot.jsonl
2974815,The percentage of patients with controlled blood pressure (<140/90 mmHg),phone calls group,no phone calls group,binary,86.0,108.0,175.0,246.0,,,,,,,2974815_zeroshot.jsonl
2974815,percentage of patients with controlled blood pressure,phone calls group,no phone calls group,binary,86.0,108.0,175.0,246.0,,,,,,,2974815_zeroshot.jsonl
3003523,Short-Form 36-Items improvement,Certolizumab 200 mg,Control,continuous,,393.0,,199.0,6.4,0.6,2.1,0.8,,,3003523_zeroshot.jsonl
3003523,Short-Form 36-Items improvement,Certolizumab 400 mg,Control,continuous,,390.0,,199.0,6.4,0.6,2.1,0.8,,,3003523_zeroshot.jsonl
3003523,Pain,Certolizumab 400 mg,Control,continuous,,390.0,,199.0,-2.5,,-0.8,,,,3003523_zeroshot.jsonl
3003523,Health-related quality of life improvement - Short-Form 36-Items improvement,Certolizumab 200 mg,Control,continuous,,393.0,,199.0,7.8,0.4,1.7,0.6,,,3003523_zeroshot.jsonl
3003523,Mental Component Summary improvement,Certolizumab 400 mg,Control,continuous,,390.0,,199.0,6.4,0.6,2.1,0.8,,,3003523_zeroshot.jsonl
3003523,Fatigue Assessment Scale improvement,Certolizumab 200 mg,Control,continuous,,393.0,,199.0,-2.6,,-0.8,,,,3003523_zeroshot.jsonl
3136370,Fibromyalgia Impact Questionnaire scores,Soy shake,Control,continuous,,25.0,,25.0,,,,,,,3136370_zeroshot.jsonl
3136370,Fibromyalgia Impact Questionnaire scores,Soy shake,Casein shake (Placebo),continuous,,25.0,,25.0,,,,,,,3136370_zeroshot.jsonl
3136370,Center for Epidemiologic Studies Depression Scale score,Soy shake,Control,continuous,,25.0,,25.0,,,,,,,3136370_zeroshot.jsonl
3136370,Center for Epidemiologic Studies Depression Scale score,Soy shake,Casein shake (Placebo),continuous,,25.0,,25.0,,,,,,,3136370_zeroshot.jsonl
3169777,adverse event profile - headache,macitentan dose of 600 mg,placebo,binary,5.0,6.0,3.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,unexpected adverse events,macitentan doses of 0.2 mg,placebo,binary,0.0,6.0,0.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,unexpected adverse events,macitentan doses of 1 mg,placebo,binary,0.0,6.0,0.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,unexpected adverse events,macitentan doses of 5 mg,placebo,binary,0.0,6.0,0.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,unexpected adverse events,macitentan doses of 25 mg,placebo,binary,0.0,6.0,0.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,unexpected adverse events,macitentan doses of 100 mg,placebo,binary,1.0,6.0,1.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,unexpected adverse events,macitentan doses of 300 mg,placebo,binary,0.0,6.0,1.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,unexpected adverse events,macitentan doses of 600 mg,placebo,binary,0.0,6.0,1.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,adverse event profile - headache,macitentan doses of 0.2 mg,placebo,binary,0.0,6.0,3.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,adverse event profile - headache,macitentan doses of 1 mg,placebo,binary,0.0,6.0,3.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,adverse event profile - headache,macitentan doses of 5 mg,placebo,binary,0.0,6.0,3.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,adverse event profile - headache,macitentan doses of 25 mg,placebo,binary,2.0,6.0,3.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,adverse event profile - headache,macitentan doses of 100 mg,placebo,binary,1.0,6.0,3.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,adverse event profile - headache,macitentan doses of 300 mg,placebo,binary,3.0,6.0,3.0,14.0,,,,,,,3169777_zeroshot.jsonl
3169777,Plasma endothelin-1 concentrations,macitentan dose of 600 mg,placebo,continuous,,6.0,,14.0,200.0,,90.0,,,,3169777_zeroshot.jsonl
3195393,Continuous restraint,After restraint reduction program,Before restraint reduction program,continuous,,562.0,,463.0,8.5,0.07,10.8,0.13,,,3195393_zeroshot.jsonl
3195393,Restraint frecuency,After restraint reduction program,Before restraint reduction program,continuous,,562.0,,463.0,13.6,,11.5,,,,3195393_zeroshot.jsonl
3195393,Intermittent restraint,After restraint reduction program,Before restraint reduction program,continuous,,562.0,,463.0,5.1,0.07,0.7,0.02,,,3195393_zeroshot.jsonl
3195393,Restraint knowledge,After restraint reduction program,Before restraint reduction program,continuous,,89.0,,97.0,6.23,,5.51,,,,3195393_zeroshot.jsonl
3214395,laryngoscopy duration,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 45",group 3 involved bispectral index (BIS) of 35,continuous,,60.0,,30.0,7.4,1.1,7.2,1.4,,,3214395_zeroshot.jsonl
3214395,laryngospasm,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 46",group 3 involved bispectral index (BIS) of 36,binary,11.0,60.0,3.0,30.0,,,,,,,3214395_zeroshot.jsonl
3214395,bronchospasm,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 47",group 3 involved bispectral index (BIS) of 37,binary,1.0,60.0,0.0,30.0,,,,,,,3214395_zeroshot.jsonl
3214395,laryngoscopy failure,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 48",group 3 involved bispectral index (BIS) of 38,binary,,60.0,,30.0,,,,,,,3214395_zeroshot.jsonl
3214395,extremity movement,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 49",group 3 involved bispectral index (BIS) of 39,binary,16.0,60.0,9.0,30.0,,,,,,,3214395_zeroshot.jsonl
3214395,awakening,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 50",group 3 involved bispectral index (BIS) of 40,continuous,,60.0,,30.0,8.75,1.3,8.8,1.6,,,3214395_zeroshot.jsonl
3263860,HbA1c reduction,Real-Time Continuous Glucose Monitoring,Control,continuous,,,,,-0.1,0.6,-0.1,0.6,,,3263860_zeroshot.jsonl
3263860,Severe hypoglycemia,Real-Time Continuous Glucose Monitoring,Control,binary,3.0,73.0,5.0,71.0,,,,,,,3263860_zeroshot.jsonl
3263860,Serious skin reactions,Real-Time Continuous Glucose Monitoring,Control,binary,0.0,74.0,0.0,72.0,,,,,,,3263860_zeroshot.jsonl
3263860,Diabetic ketoacidosis,Real-Time Continuous Glucose Monitoring,Control,binary,0.0,74.0,0.0,72.0,,,,,,,3263860_zeroshot.jsonl
3263860,PAID questionnaire fear of hypoglycemia,Real-Time Continuous Glucose Monitoring,Control,continuous,,69.0,,68.0,44.0,17.0,49.0,16.0,,,3263860_zeroshot.jsonl
3276927,relieving factors in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19.0,,19.0,3.0,,2.0,,,,3276927_zeroshot.jsonl
3276927,effective in the treatment of reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19.0,,19.0,,,,,,,3276927_zeroshot.jsonl
3276927,frequency of occurrence in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19.0,,19.0,2.0,,12.0,,,,3276927_zeroshot.jsonl
3276927,"symptoms of hernia such as heaviness, fullness and pain",post-Yoga,pre-Yoga,continuous,,19.0,,19.0,,,,,,,3276927_zeroshot.jsonl
3276927,pain in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19.0,,19.0,1.0,,6.0,,,,3276927_zeroshot.jsonl
3276927,aggravating factors in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19.0,,19.0,1.0,,4.0,,,,3276927_zeroshot.jsonl
3278655,maximum total point motion (MTPM),The trabecular metal tibial monoblock component (TM),cemented component.,continuous,,27.0,,18.0,0.98,,0.79,,,,3278655_zeroshot.jsonl
3278655,subsidence,The trabecular metal tibial monoblock component (TM),cemented component.,continuous,,27.0,,18.0,-0.38,0.37,-0.04,0.11,,,3278655_zeroshot.jsonl
3278655,"The proportion of ""at risk"" components at 5 years",The trabecular metal tibial monoblock component (TM),cemented component.,binary,0.0,27.0,2.0,18.0,,,,,,,3278655_zeroshot.jsonl
3309311,differences in the disc herniation,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,20.0,23.0,6.0,19.0,,,,,,,3309311_zeroshot.jsonl
3309311,differences in the LDD,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,23.0,23.0,9.0,19.0,,,,,,,3309311_zeroshot.jsonl
3309311,differences in the annulus tear,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,23.0,23.0,5.0,19.0,,,,,,,3309311_zeroshot.jsonl
3309311,differences in the HIZ,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,14.0,23.0,4.0,19.0,,,,,,,3309311_zeroshot.jsonl
3309311,The proportion of HIZ incidence,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)",adults with LBP with radicular pain (group C),binary,14.0,23.0,3.0,18.0,,,,,,,3309311_zeroshot.jsonl
3309311,The proportion of HIZ incidence,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,14.0,23.0,4.0,19.0,,,,,,,3309311_zeroshot.jsonl
3321528,wrist flexion,electrical muscle stimulation (EMS),control,continuous,,24.0,,28.0,,,,,,,3321528_zeroshot.jsonl
3321528,hip flexion,electrical muscle stimulation (EMS),control,continuous,,24.0,,28.0,,,,,,,3321528_zeroshot.jsonl
3321528,knee extension,electrical muscle stimulation (EMS),control,continuous,,24.0,,28.0,,,,,,,3321528_zeroshot.jsonl
3321528,ankle dorsiflexion,electrical muscle stimulation (EMS),control,continuous,,24.0,,28.0,,,,,,,3321528_zeroshot.jsonl
3321528,handgrip strength,Intensive Care Unit acquired weakness (ICU-AW),without an ICU-AW diagnosis,continuous,,7.0,,14.0,6.6,4.4,23.4,8.9,,,3321528_zeroshot.jsonl
3321528,the total MRC score of the legs,electrical muscle stimulation (EMS),control,continuous,,24.0,,28.0,,,,,,,3321528_zeroshot.jsonl
3475525,Correct selection of the healthier product,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,73.3,6.9,67.8,10.3,,,3475525_zeroshot.jsonl
3475525,Correct selection of the healthier product,MTL+caloric intake group,TL+SNL group,continuous,,90.0,,95.0,73.3,6.9,65.8,7.3,,,3475525_zeroshot.jsonl
3475525,Correct selection of the healthier product,choices group,No label group,continuous,,98.0,,99.0,72.5,13.2,67.8,10.3,,,3475525_zeroshot.jsonl
3475525,Correct selection of the healthier product,choices group,TL+SNL group,continuous,,98.0,,95.0,72.5,13.2,65.8,7.3,,,3475525_zeroshot.jsonl
3475525,Taste perception,MTL group,No label group,continuous,,98.0,,99.0,5.6,1.4,5.8,1.4,,,3475525_zeroshot.jsonl
3475525,Taste perception,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,5.4,1.4,5.8,1.4,,,3475525_zeroshot.jsonl
3475525,Taste perception,MTL group,choices group,continuous,,98.0,,98.0,5.6,1.4,5.3,1.5,,,3475525_zeroshot.jsonl
3475525,Taste perception,MTL+caloric intake group,choices group,continuous,,90.0,,98.0,5.4,1.4,5.3,1.5,,,3475525_zeroshot.jsonl
3475525,intent of purchase,MTL group,No label group,continuous,,98.0,,99.0,3.8,1.4,4.1,1.5,,,3475525_zeroshot.jsonl
3475525,intent of purchase,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,3.6,1.5,4.1,1.5,,,3475525_zeroshot.jsonl
3475525,intent of purchase,MTL group,choices group,continuous,,98.0,,98.0,3.8,1.4,4.1,1.7,,,3475525_zeroshot.jsonl
3475525,intent of purchase,MTL+caloric intake group,choices group,continuous,,90.0,,98.0,3.6,1.5,4.1,1.7,,,3475525_zeroshot.jsonl
3475525,Scores on the saturated fat quiz,MTL group,No label group,continuous,,98.0,,99.0,90.7,20.4,33.6,16.3,,,3475525_zeroshot.jsonl
3475525,Scores on the saturated fat quiz,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,92.3,15.1,33.6,16.3,,,3475525_zeroshot.jsonl
3475525,Scores on the saturated fat quiz,MTL group,choices group,continuous,,98.0,,98.0,90.7,20.4,35.7,15.9,,,3475525_zeroshot.jsonl
3475525,Scores on the saturated fat quiz,MTL+caloric intake group,choices group,continuous,,90.0,,98.0,92.3,15.1,35.7,15.9,,,3475525_zeroshot.jsonl
3475525,Scores on sugar quiz,MTL group,No label group,continuous,,98.0,,99.0,90.0,20.7,47.2,19.6,,,3475525_zeroshot.jsonl
3475525,Scores on sugar quiz,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,92.6,15.5,47.2,19.6,,,3475525_zeroshot.jsonl
3475525,Scores on sugar quiz,MTL group,choices group,continuous,,98.0,,98.0,90.0,20.7,41.9,19.4,,,3475525_zeroshot.jsonl
3475525,Scores on sugar quiz,MTL+caloric intake group,choices group,continuous,,90.0,,98.0,92.6,15.5,41.9,19.4,,,3475525_zeroshot.jsonl
3475525,Scores on sodium quiz,MTL group,No label group,continuous,,98.0,,99.0,93.5,16.4,42.6,20.7,,,3475525_zeroshot.jsonl
3475525,Scores on sodium quiz,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,94.1,15.6,42.6,20.7,,,3475525_zeroshot.jsonl
3475525,Scores on sodium quiz,MTL group,choices group,continuous,,98.0,,98.0,93.5,16.4,47.1,21.1,,,3475525_zeroshot.jsonl
3475525,Scores on sodium quiz,MTL+caloric intake group,choices group,continuous,,90.0,,98.0,94.1,15.6,47.1,21.1,,,3475525_zeroshot.jsonl
3493722,eradication rate of H. pylori in ITT,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,71.0,85.0,72.0,84.0,,,,,,,3493722_zeroshot.jsonl
3493722,eradication rate of H. pylori in PP,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,71.0,81.0,72.0,81.0,,,,,,,3493722_zeroshot.jsonl
3493722,side effects,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,19.0,85.0,32.0,84.0,,,,,,,3493722_zeroshot.jsonl
3493722,good compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,74.0,81.0,74.0,81.0,,,,,,,3493722_zeroshot.jsonl
3493722,well compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,8.0,81.0,4.0,81.0,,,,,,,3493722_zeroshot.jsonl
3493722,poor compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,2.0,81.0,3.0,81.0,,,,,,,3493722_zeroshot.jsonl
3496170,Self-report questionnaire,Biperiden,Placebo,continuous,,17.0,,17.0,,,,,,,3496170_zeroshot.jsonl
3496170,Learned irrelevance index,Biperiden,Placebo,continuous,,15.0,,15.0,,,,,,,3496170_zeroshot.jsonl
3496170,P3a amplitude,Biperiden,Placebo,continuous,,15.0,,15.0,,,,,,,3496170_zeroshot.jsonl
3496170,P3a latency,Biperiden,Placebo,continuous,,15.0,,15.0,,,,,,,3496170_zeroshot.jsonl
3496170,N1 latency,Biperiden,Placebo,continuous,,15.0,,15.0,,,,,,,3496170_zeroshot.jsonl
3496170,N1 amplitude,Biperiden,Placebo,continuous,,15.0,,15.0,,,,,,,3496170_zeroshot.jsonl
3504298,Depressive symptoms,Face-based attentional bias modification,Placebo,continuous,,16.0,,14.0,,,,,,,3504298_zeroshot.jsonl
3504298,Depressive symptoms,Word-based attentional bias modification,Placebo,continuous,,16.0,,15.0,,,,,,,3504298_zeroshot.jsonl
3504298,Anxious symptoms,Face-based attentional bias modification,Placebo,continuous,,16.0,,14.0,,,,,,,3504298_zeroshot.jsonl
3504298,Attentional Function,Word-based attentional bias modification,Face-based attentional bias modification,continuous,,16.0,,16.0,,,,,,,3504298_zeroshot.jsonl
3504298,Difference of cortisol on waking and the highest level of following samples,Word-based attentional bias modification,Placebo,continuous,,16.0,,15.0,,,,,,,3504298_zeroshot.jsonl
3508963,Pain relief,Intravenous lidocaine,Intravenous morphine,continuous,,120.0,,120.0,65.0,,53.0,,,,3508963_zeroshot.jsonl
3508963,Response to treatment,Intravenous lidocaine,Intravenous morphine,binary,108.0,120.0,84.0,120.0,,,,,,,3508963_zeroshot.jsonl
3508963,Baseline characteristics - age,Intravenous lidocaine,Intravenous morphine,continuous,,120.0,,120.0,35.23,12.37,37.71,11.08,,,3508963_zeroshot.jsonl
3508963,Baseline characteristics - hydronephrosis in left kidney,Intravenous lidocaine,Intravenous morphine,binary,52.0,120.0,52.0,120.0,,,,,,,3508963_zeroshot.jsonl
3508963,Baseline characteristics - hydronephrosis in right kidney,Intravenous lidocaine,Intravenous morphine,binary,57.0,120.0,53.0,120.0,,,,,,,3508963_zeroshot.jsonl
3508963,Baseline characteristics - did not have hydronephrosis,Intravenous lidocaine,Intravenous morphine,binary,11.0,120.0,15.0,120.0,,,,,,,3508963_zeroshot.jsonl
3508963,Baseline characteristics - history of reurrent stone,Intravenous lidocaine,Intravenous morphine,binary,49.0,119.0,64.0,120.0,,,,,,,3508963_zeroshot.jsonl
3508963,Baseline characteristics - history of first stone,Intravenous lidocaine,Intravenous morphine,binary,70.0,119.0,56.0,120.0,,,,,,,3508963_zeroshot.jsonl
3508963,Baseline characteristics - right kidney stone,Intravenous lidocaine,Intravenous morphine,binary,60.0,120.0,57.0,120.0,,,,,,,3508963_zeroshot.jsonl
3508963,Baseline characteristics - left kidney stone,Intravenous lidocaine,Intravenous morphine,binary,60.0,120.0,63.0,120.0,,,,,,,3508963_zeroshot.jsonl
3508963,Pain score after 5 minutes,Intravenous lidocaine,Intravenous morphine,continuous,,120.0,,120.0,3.18,2.27,4.45,2.16,,,3508963_zeroshot.jsonl
3510731,Clicked on Results link,received the debriefing information in the body of an email with links to protocol and results pages,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,binary,247.0,6051.0,515.0,5892.0,,,,,,,3510731_zeroshot.jsonl
3510731,Clicked on Protocol link,received the debriefing information in the body of an email with links to protocol and results pages,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,binary,202.0,6051.0,362.0,5892.0,,,,,,,3510731_zeroshot.jsonl
3510731,Median time in seconds (interquartile range) - Results link,received the debriefing information in the body of an email with links to protocol and results pages,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,continuous,,247.0,,515.0,25.0,37.2,25.3,35.8,,,3510731_zeroshot.jsonl
3510731,Median time in seconds (interquartile range) - Protocol link,received the debriefing information in the body of an email with links to protocol and results pages,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,continuous,,202.0,,362.0,3.5,5.4,3.6,3.9,,,3510731_zeroshot.jsonl
3546023,Urine cotinine levels,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,20.0,,19.0,1.179,0.738,0.047,0.017,,,3546023_zeroshot.jsonl
3546023,serum α1-antitrypsin,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,30.0,,19.0,1.75,0.39,1.45,0.24,,,3546023_zeroshot.jsonl
3546023,The percentage of B cells,200 mg/day palmvitee nonsmokers,baseline,continuous,,29.0,,29.0,13.72,4.53,11.97,4.0,,,3546023_zeroshot.jsonl
3546023,The percentage of B cells,200 mg/day palmvitee smokers,baseline,continuous,,30.0,,30.0,14.4,4.03,14.06,3.81,,,3546023_zeroshot.jsonl
3546023,The percentage of NK cells,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,30.0,,29.0,19.03,7.82,24.72,8.78,,,3546023_zeroshot.jsonl
3546023,tocopherol levels,200 mg/day palmvitee smokers,baseline,continuous,,30.0,,30.0,14.11,3.89,11.39,3.06,,,3546023_zeroshot.jsonl
3546023,tocotrienol levels,200 mg/day palmvitee smokers,baseline,continuous,,30.0,,30.0,587.68,87.5,59.49,4.21,,,3546023_zeroshot.jsonl
3546023,tocopherol levels,200 mg/day palmvitee nonsmokers,baseline,continuous,,29.0,,29.0,14.56,3.06,11.75,2.27,,,3546023_zeroshot.jsonl
3546023,tocotrienol levels,200 mg/day palmvitee nonsmokers,baseline,continuous,,29.0,,29.0,675.16,150.0,63.6,5.67,,,3546023_zeroshot.jsonl
3546023,CD4+/CD8+ ratio,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,30.0,,29.0,1.19,0.43,1.03,0.53,,,3546023_zeroshot.jsonl
3577738,website use in terms of the number of pages visited,website with social presence elements.,website without social presence elements.,continuous,,231.0,,227.0,7.5,4.0,8.0,3.8,,,3577738_zeroshot.jsonl
3577738,website use in terms of time on the website,website with social presence elements.,website without social presence elements.,continuous,,231.0,,227.0,151.0,117.4,150.8,107.8,,,3577738_zeroshot.jsonl
3577738,focused on the social presence elements in terms of frequency,website with social presence elements.,website without social presence elements.,continuous,,19.0,,19.0,,,,,,,3577738_zeroshot.jsonl
3577738,focused on the social presence elements in terms of duration,website with social presence elements.,website without social presence elements.,continuous,,19.0,,19.0,,,,,,,3577738_zeroshot.jsonl
3577738,efficiency,website with social presence elements.,website without social presence elements.,continuous,,231.0,,227.0,,,,,,,3577738_zeroshot.jsonl
3577738,effectiveness,website with social presence elements.,website without social presence elements.,continuous,,231.0,,227.0,,,,,,,3577738_zeroshot.jsonl
3577738,enjoyment,website with social presence elements.,website without social presence elements.,continuous,,231.0,,227.0,,,,,,,3577738_zeroshot.jsonl
3577738,active trust,website with social presence elements.,website without social presence elements.,continuous,,231.0,,227.0,,,,,,,3577738_zeroshot.jsonl
3577738,interest,website with social presence elements.,website without social presence elements.,continuous,,231.0,,227.0,,,,,,,3577738_zeroshot.jsonl
3580751,mean ± SD length of hospital stay between periods 1 and 2 in patients who did not suffer from VAP,Interrupted surveillance unit A,"Continuous surveillance, unit B",continuous,,,,,,,,,,,3580751_zeroshot.jsonl
3648394,LF:HF component of HRV,10-week yoga program,Control,continuous,,18.0,,19.0,0.35,0.43,0.04,0.38,,,3648394_zeroshot.jsonl
3648394,Push-up test,10-week yoga program,Control,continuous,,18.0,,19.0,21.0,11.0,20.0,13.0,,,3648394_zeroshot.jsonl
3648394,Quality of life - PCS (SF36),10-week yoga program,Control,continuous,,18.0,,19.0,47.5,2.7,46.9,4.8,,,3648394_zeroshot.jsonl
3648394,Quality of life - MCS (SF36),10-week yoga program,Control,continuous,,18.0,,19.0,47.5,10.6,48.5,7.7,,,3648394_zeroshot.jsonl
3648394,pNN50,10-week yoga program,Control,continuous,,18.0,,19.0,20.7,25.3,19.4,18.4,,,3648394_zeroshot.jsonl
3648394,Flexibility,10-week yoga program,Control,continuous,,18.0,,19.0,31.0,8.7,26.4,10.4,,,3648394_zeroshot.jsonl
3654355,Body weight,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,-17.5,6.1,-0.5,2.8,,,3654355_zeroshot.jsonl
3654355,Fat mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,-15.7,5.3,-0.4,5.0,,,3654355_zeroshot.jsonl
3654355,Visceral fat,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,-82.3,31.6,4.3,22.7,,,3654355_zeroshot.jsonl
3654355,Baseline Height,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,173.2,8.6,172.3,10.4,,,3654355_zeroshot.jsonl
3654355,Baseline body mass index,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,42.8,4.6,42.8,6.3,,,3654355_zeroshot.jsonl
3654355,baseline body weight,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,128.9,19.4,127.1,21.6,,,3654355_zeroshot.jsonl
3654355,baseline fat mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,60.5,11.0,60.4,13.5,,,3654355_zeroshot.jsonl
3654355,baseline fat-free mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,68.3,13.2,67.1,12.8,,,3654355_zeroshot.jsonl
3654355,baseline skeletal muscle mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,38.4,7.9,37.9,7.4,,,3654355_zeroshot.jsonl
3654355,baseline visceral fat area,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,255.7,64.7,245.6,66.3,,,3654355_zeroshot.jsonl
3687098,adverse event of constipation,sitagliptin 100 mg/day,comparator agent,binary,,7726.0,,6885.0,2.3,,1.8,,,,3687098_zeroshot.jsonl
3687098,The incidence rates of malignancy,sitagliptin 100 mg/day,comparator agent,binary,,7726.0,,6885.0,0.9,,0.93,,,,3687098_zeroshot.jsonl
3687098,The incidence rates of pancreatitis,sitagliptin 100 mg/day,comparator agent,binary,,7726.0,,6885.0,0.1,,0.1,,,,3687098_zeroshot.jsonl
3687098,The incidence of the composite endpoint of rash,sitagliptin 100 mg/day,comparator agent,binary,,7726.0,,6885.0,1.7,,1.1,,,,3687098_zeroshot.jsonl
3751573,improvement in nursing,phase I externship program,phase II corporate-academic cooperation program,continuous,,19.0,,23.0,22.95,24.33,36.6,29.01,,,3751573_zeroshot.jsonl
3786549,Improvement in Vaginal Maturation Index,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44.0,,44.0,35.2,21.7,9.9,14.5,,,3786549_zeroshot.jsonl
3786549,Baseline characteristics: menopause,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44.0,,44.0,13.11,7.02,13.0,6.94,,,3786549_zeroshot.jsonl
3786549,Baseline characteristics: height,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44.0,,44.0,154.86,5.45,153.43,5.88,,,3786549_zeroshot.jsonl
3786549,Baseline characteristics: weight,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44.0,,44.0,56.16,8.1,57.82,8.24,,,3786549_zeroshot.jsonl
3786549,Baseline characteristics: deliveries,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44.0,,44.0,2.14,1.76,2.64,1.79,,,3786549_zeroshot.jsonl
3877023,quantitative contour sharpness of the Cervicothoracic Spine,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,18.0,,21.0,0.8,0.1,1.1,0.2,,,3877023_zeroshot.jsonl
3877023,quantitative contour sharpness of the thoracolumbar spine,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,30.0,,34.0,0.9,0.1,1.5,0.4,,,3877023_zeroshot.jsonl
3877023,contrast-to-noise ratios (CNR) of Cervicothoracic Spine - T2w sagittal Cerebrospinal fluid – Spinal cord,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,18.0,,21.0,18.1,11.6,9.3,5.5,,,3877023_zeroshot.jsonl
3877023,contrast-to-noise ratios (CNR) of Thoracolumbar Spine - T2w sagittal Cerebrospinal fluid – Spinal cord,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,30.0,,34.0,22.3,13.2,14.0,5.6,,,3877023_zeroshot.jsonl
3877023,contrast-to-noise ratios (CNR) of Cervicothoracic Spine - T2w sagittal Cerebrospinal fluid – Vertebral bone,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,18.0,,21.0,19.3,10.3,8.2,5.7,,,3877023_zeroshot.jsonl
3877023,contrast-to-noise ratios (CNR) of Thoracolumbar Spine - T2w sagittal Cerebrospinal fluid – Vertebral bone,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,30.0,,34.0,24.0,12.9,11.7,6.3,,,3877023_zeroshot.jsonl
3877023,Scanning times,high-field horizontal open MR scanner,short-bore MR scanner,continuous,,55.0,,48.0,31.7,21.6,19.8,8.5,,,3877023_zeroshot.jsonl
3877023,The mean signal-to-noise (SNR) values,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,,,,17.97,6.58,11.28,4.35,,,3877023_zeroshot.jsonl
3912320,Correct response rate for 500 Hz frequency,Occupational noise,Control,continuous,,19.0,,10.0,31.9,,55.9,,,,3912320_zeroshot.jsonl
3912320,"Correct response rate for 4,000 Hz frequency",Occupational noise,Control,continuous,,19.0,,10.0,28.07,,53.07,,,,3912320_zeroshot.jsonl
3912320,"Correct response rate for 2,000 Hz frequency",Occupational noise,Control,continuous,,19.0,,10.0,30.4,,51.4,,,,3912320_zeroshot.jsonl
3929816,Baseline characteristics and general anesthesia procedure,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,continuous,,10.0,,10.0,,,,,,,3929816_zeroshot.jsonl
3929816,Pathologic changes in the liver,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,binary,,10.0,,10.0,,,,,,,3929816_zeroshot.jsonl
3929816,Pathologic changes in the kidneys,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,binary,10.0,10.0,0.0,10.0,,,,,,,3929816_zeroshot.jsonl
3936115,The number of diverticulitis clinical symptom occurrences during 12months,Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,binary,2.0,30.0,7.0,22.0,,,,,,,3936115_zeroshot.jsonl
3936115,the number of abdominal ultrasound examinations performed for suspected diverticulitis and subsequent number of diverticulitis diagnosed based on abdominal US,Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,binary,1.0,30.0,5.0,22.0,,,,,,,3936115_zeroshot.jsonl
3936115,"Subjective improvement in observed symptoms based on a single closed-end question (yes or no answer): ""Did you observe adequate relief of diverticulosis related to abdominal pain or discomfort within the past 12 months?""",Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,binary,17.0,30.0,5.0,22.0,,,,,,,3936115_zeroshot.jsonl
4033571,Overall seizure median percent improvement,Extended-release oxcarbazepine 2400 mg,Control,continuous,,111.0,,117.0,42.9,,28.7,,,,4033571_zeroshot.jsonl
4033571,Adverse effects,Extended-release oxcarbazepine 1200 mg,Control,binary,69.0,122.0,67.0,121.0,,,,,,,4033571_zeroshot.jsonl
4033571,Overall seizure median percent reduction,Extended-release oxcarbazepine 1200 mg,Control,continuous,,109.0,,117.0,38.2,,28.7,,,,4033571_zeroshot.jsonl
4033571,Adverse effects,Extended-release oxcarbazepine 2400 mg,Control,binary,85.0,123.0,67.0,121.0,,,,,,,4033571_zeroshot.jsonl
4033571,Seizure median percent improvement in North America,Extended-release oxcarbazepine 1200 mg,Control,continuous,,40.0,,41.0,34.5,,13.3,,,,4033571_zeroshot.jsonl
4033571,Seizure median percent improvement in North America,Extended-release oxcarbazepine 2400 mg,Control,continuous,,35.0,,41.0,52.7,,13.3,,,,4033571_zeroshot.jsonl
4132222,decrease in average lesion,application of a canola phenolic acid-based cream (CPA),placebo,continuous,,27.0,,15.0,4.71,,12.57,,,,4132222_zeroshot.jsonl
4132222,"higher prevalence of lesion scabbing, a sign of healing",application of a canola phenolic acid-based cream (CPA),placebo,binary,,,,,,,,,,,4132222_zeroshot.jsonl
4140238,ocular itching for visit 3B at 7 min,bepotastine besilate ophthalmic solution (BBOS) 1.5%,placebo,continuous,,68.0,,69.0,1.2,,2.1,,,,4140238_zeroshot.jsonl
4144850,Independent household latrines number,Total Sanitation Campaign,Control,binary,631.0,1522.0,342.0,1512.0,,,,,,,4144850_zeroshot.jsonl
4144850,Open defecation - adult men,Total Sanitation Campaign,Control,binary,1138.0,1525.0,1274.0,1514.0,,,,,,,4144850_zeroshot.jsonl
4144850,Open defecation - adult women,Total Sanitation Campaign,Control,binary,1116.0,1525.0,1265.0,1514.0,,,,,,,4144850_zeroshot.jsonl
4144850,Open defecation - children,Total Sanitation Campaign,Control,binary,1280.0,1525.0,1351.0,1514.0,,,,,,,4144850_zeroshot.jsonl
4144850,Helminth infections,Total Sanitation Campaign,Control,binary,34.0,581.0,32.0,569.0,,,,,,,4144850_zeroshot.jsonl
4144850,Anemia,Total Sanitation Campaign,Control,binary,1079.0,1919.0,977.0,1922.0,,,,,,,4144850_zeroshot.jsonl
4144850,Sanitation facility improvement,Total Sanitation Campaign,Control,binary,631.0,1522.0,342.0,1512.0,,,,,,,4144850_zeroshot.jsonl
4144850,E. coli contaminated water,Total Sanitation Campaign,Control,binary,310.0,404.0,331.0,403.0,,,,,,,4144850_zeroshot.jsonl
4173437,Postoperatively hematocrit,Tranexamic acid,Control,continuous,,30.0,,30.0,30.14,2.2,29.36,1.8,,,4173437_zeroshot.jsonl
4173437,Complications,Tranexamic acid,Control,binary,0.0,30.0,0.0,30.0,,,,,,,4173437_zeroshot.jsonl
4173437,Adverse effects,Tranexamic acid,Control,binary,0.0,30.0,0.0,30.0,,,,,,,4173437_zeroshot.jsonl
4173437,Total blood loss,Tranexamic acid,Control,continuous,,30.0,,30.0,576.0,53.0,823.0,74.0,,,4173437_zeroshot.jsonl
4173437,Coagulation profile,Tranexamic acid,Control,continuous,,30.0,,30.0,,,,,,,4173437_zeroshot.jsonl
4173437,Crystalloid solution needed,Tranexamic acid,Control,continuous,,30.0,,30.0,,,,,,,4173437_zeroshot.jsonl
4183415,completion of each dose at the correct time,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,binary,150.0,453.0,147.0,451.0,,,,,,,4183415_zeroshot.jsonl
4183415,patient adherence,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,binary,309.0,453.0,315.0,451.0,,,,,,,4183415_zeroshot.jsonl
4183415,Completed treatment,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,binary,309.0,453.0,315.0,451.0,,,,,,,4183415_zeroshot.jsonl
4188762,withdrawal response of rocuronium,lidocaine,normal saline,binary,6.0,30.0,26.0,30.0,,,,,,,4188762_zeroshot.jsonl
4188762,withdrawal response of rocuronium,ketamine,normal saline,binary,9.0,30.0,26.0,30.0,,,,,,,4188762_zeroshot.jsonl
4188762,withdrawal response of rocuronium,remifentanil,normal saline,binary,0.0,30.0,26.0,30.0,,,,,,,4188762_zeroshot.jsonl
4188762,heart rate,remifentanil,normal saline,continuous,,30.0,,30.0,,,,,,,4188762_zeroshot.jsonl
4188762,heart rate,remifentanil,lidocaine,continuous,,30.0,,30.0,,,,,,,4188762_zeroshot.jsonl
4188762,heart rate,remifentanil,ketamine,continuous,,30.0,,30.0,,,,,,,4188762_zeroshot.jsonl
4188762,mean blood pressure,remifentanil,normal saline,continuous,,30.0,,30.0,,,,,,,4188762_zeroshot.jsonl
4188762,mean blood pressure,remifentanil,lidocaine,continuous,,30.0,,30.0,,,,,,,4188762_zeroshot.jsonl
4188762,mean blood pressure,remifentanil,"normal saline, lidocaine, or ketamine",continuous,,30.0,,90.0,,,,,,,4188762_zeroshot.jsonl
4210722,vaccination certificates were submitted,a separate reminder card 4 days before the appointment (IG3),no further reminder (IG1),binary,94.0,102.0,84.0,104.0,,,,,,,4210722_zeroshot.jsonl
4210722,vaccination certificates were submitted,a separate reminder card 4 days before the appointment (IG3),reminder card together with the appointment letter (IG2),binary,94.0,102.0,91.0,107.0,,,,,,,4210722_zeroshot.jsonl
4210722,use of a reminder card,a separate reminder card 4 days before the appointment (IG3); reminder card together with the appointment letter (IG2);,no further reminder (IG1),binary,185.0,209.0,84.0,104.0,,,,,,,4210722_zeroshot.jsonl
4215531,alpha power,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,,,,,,,4215531_zeroshot.jsonl
4215531,alpha power,facial affect training (FAT) in 20 daily 1-hour sessions,treatment as usual (TAU),continuous,,19.0,,19.0,,,,,,,4215531_zeroshot.jsonl
4215531,MCCB performance : Processing Speed,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,44.6,12.2,39.5,10.6,,,4215531_zeroshot.jsonl
4215531,MCCB performance : Attentional Vigilance,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,38.5,11.8,33.6,11.5,,,4215531_zeroshot.jsonl
4215531,MCCB performance : Visual Learning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,49.4,14.0,42.8,12.8,,,4215531_zeroshot.jsonl
4215531,MCCB performance : Working Memory,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,48.2,9.2,44.6,10.2,,,4215531_zeroshot.jsonl
4215531,MCCB performance : Verbal Learning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,47.1,10.0,46.2,9.9,,,4215531_zeroshot.jsonl
4215531,MCCB performance : Reasoning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,47.9,8.8,44.5,10.7,,,4215531_zeroshot.jsonl
4215531,MCCB performance : Social Cognition,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,39.3,10.4,39.3,11.1,,,4215531_zeroshot.jsonl
4230312,improvement of disorder,quetiapine 600 mg/day,placebo,continuous,,289.0,,204.0,-14.88,,-11.61,,,,4230312_zeroshot.jsonl
4230312,improvement of disorder,quetiapine 300 mg/day,placebo,continuous,,283.0,,204.0,-15.58,,-11.61,,,,4230312_zeroshot.jsonl
4319071,High-energy snack intake,Individual cognition and self-regulation processes intervention,Control,continuous,,808.0,,808.0,-0.51,,-2.43,,,,4319071_zeroshot.jsonl
4319071,High-energy snack intake,Intervention + targeting environmental-level factors,Control,continuous,,808.0,,808.0,-0.81,,-2.43,,,,4319071_zeroshot.jsonl
4319071,Vegetable intake,Intervention + targeting environmental-level factors,Control,continuous,,1014.0,,1014.0,20.76,,12.72,,,,4319071_zeroshot.jsonl
4319071,Vegetable intake,Intervention + targeting environmental-level factors,Individual cognition and self-regulation processes intervention,continuous,,1014.0,,1014.0,20.76,,24.21,,,,4319071_zeroshot.jsonl
4319071,Fruit intake,Intervention + targeting environmental-level factors,Control,continuous,,803.0,,803.0,0.77,,0.37,,,,4319071_zeroshot.jsonl
4319071,Fruit intake,Intervention + targeting environmental-level factors,Individual cognition and self-regulation processes intervention,continuous,,803.0,,803.0,0.77,,0.53,,,,4319071_zeroshot.jsonl
4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Deep-cooling,Mild-cooling,binary,5.0,9.0,7.0,10.0,,,,,,,4323894_zeroshot.jsonl
4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Deep-cooling,No cooling,binary,5.0,9.0,2.0,13.0,,,,,,,4323894_zeroshot.jsonl
4323894,Rate of complications,Mild-cooling or deep-cooling,No cooling,binary,10.0,19.0,6.0,13.0,,,,,,,4323894_zeroshot.jsonl
4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Mild-cooling,No cooling,binary,7.0,10.0,2.0,13.0,,,,,,,4323894_zeroshot.jsonl
4355974,Days of wheeze,BostonBreathes system,Control,continuous,,28.0,,14.0,-1.4,,-4.2,,,,4355974_zeroshot.jsonl
4355974,ER visits,BostonBreathes system,Control,binary,1.0,26.0,1.0,14.0,,,,,,,4355974_zeroshot.jsonl
4355974,Days limited activity from asthma,BostonBreathes system,Control,continuous,,28.0,,14.0,-0.2,,-1.8,,,,4355974_zeroshot.jsonl
4355974,Knowledge,BostonBreathes system,Control,binary,9.0,12.0,3.0,8.0,,,,,,,4355974_zeroshot.jsonl
4355974,School days missed for asthma,BostonBreathes system,Control,continuous,,28.0,,14.0,-0.2,,-0.4,,,,4355974_zeroshot.jsonl
4355974,Days patient had to slow down,BostonBreathes system,Control,continuous,,28.0,,14.0,-1.4,,-0.4,,,,4355974_zeroshot.jsonl
4357072,improvement in symptom scores,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,continuous,,15.0,,15.0,0.2,0.4,0.8,0.6,,,4357072_zeroshot.jsonl
4357072,reduction in burning sensation,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,continuous,,15.0,,15.0,1.0,2.1,5.3,6.1,,,4357072_zeroshot.jsonl
4357072,reduction in erythematous area,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,binary,14.0,15.0,10.0,15.0,,,,,,,4357072_zeroshot.jsonl
4357072,reappearance of erythematous areas after 2 months posttreatment,pimecrolimus,triamcinolone acetate,binary,1.0,15.0,5.0,15.0,,,,,,,4357072_zeroshot.jsonl
4411165,tympanic temperature from Pre to P20 (-0.28 ±0.11°C),"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10.0,,10.0,-0.28,0.11,-0.14,0.05,,,4411165_zeroshot.jsonl
4411165,systolic BP,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10.0,,10.0,,,,,,,4411165_zeroshot.jsonl
4411165,diastolic BP,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10.0,,10.0,,,,,,,4411165_zeroshot.jsonl
4411165,effects of cryostimulation on the ANS - heart rate,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10.0,,10.0,-7.7,2.3,-5.02,1.07,,,4411165_zeroshot.jsonl
4411165,Tskin of the head,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10.0,,10.0,-7.6,,-1.5,,,,4411165_zeroshot.jsonl
4450164,ureteropelvic junction obstruction,internal drainage group,stentless cases,binary,0.0,30.0,1.0,52.0,,,,,,,4450164_zeroshot.jsonl
4458006,amplitude of whisking,facial nerve transection and subsequent repair either at the main trunk of the nerve (group 1),"2 cm distally, at the main bifurcation (group 2)",continuous,,12.0,,12.0,17.2,,5.9,,,,4458006_zeroshot.jsonl
4467620,decrease in exercise intensity as time elapsed (at time 10),Hot + Cooling conditions,Hot conditions,continuous,,8.0,,8.0,114.6,35.6,123.9,30.2,,,4467620_zeroshot.jsonl
4467620,weight reduction,Hot + Cooling conditions,Hot conditions,continuous,,8.0,,8.0,0.37,0.22,0.41,0.07,,,4467620_zeroshot.jsonl
4467620,accuracy of the cognitive tasks,Exercise - Hot + Cooling conditions,At rest - Hot + Cooling conditions,continuous,,8.0,,8.0,,,,,,,4467620_zeroshot.jsonl
4467620,accuracy of the cognitive tasks,Exercise - Hot condition,At rest - Hot condition,continuous,,8.0,,8.0,,,,,,,4467620_zeroshot.jsonl
4467620,differences in the accuracy,Hot + Cooling conditions,Hot conditions,continuous,,8.0,,8.0,,,,,,,4467620_zeroshot.jsonl
4483334,Total weight percentage of calcium,CPP-ACP plus laser (group D),Distilled and deionized water (group A),continuous,,20.0,,20.0,18.06,15.68,6.98,4.42,,,4483334_zeroshot.jsonl
4483334,Total weight percentage of calcium,CPP-ACP plus laser (group D),Nd:YAG laser (group B),continuous,,20.0,,20.0,18.06,15.68,9.36,5.49,,,4483334_zeroshot.jsonl
4483334,Total weight percentage of calcium,CPP-ACP plus laser (group D),CPP-ACP crème (group C),continuous,,20.0,,20.0,18.06,15.68,13.17,7.1,,,4483334_zeroshot.jsonl
4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),Distilled and deionized water (group A),continuous,,20.0,,20.0,12.68,10.5,6.99,3.37,,,4483334_zeroshot.jsonl
4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),Nd:YAG laser (group B),continuous,,20.0,,20.0,12.68,10.5,8.19,3.3,,,4483334_zeroshot.jsonl
4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),CPP-ACP crème (group C),continuous,,20.0,,20.0,12.68,10.5,10.12,2.72,,,4483334_zeroshot.jsonl
4486927,"The SVR rates if the patients had IL-28B rs8099917 TT genotype, and GT/GG genotype",peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,62.0,88.0,37.0,84.0,,,,,,,4486927_zeroshot.jsonl
4486927,The early virologic response (EVR),peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,86.0,94.0,82.0,93.0,,,,,,,4486927_zeroshot.jsonl
4486927,the end-of-treatment virologic response,peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,83.0,94.0,75.0,93.0,,,,,,,4486927_zeroshot.jsonl
4486927,The SVR rates when the patients had BMI >30 kg/m2,peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,10.0,19.0,6.0,12.0,,,,,,,4486927_zeroshot.jsonl
4493951,the incidence of postoperative nausea and vomiting (PONV),H1(haloperidol 1 mg),H0 (saline),binary,14.0,49.0,27.0,50.0,,,,,,,4493951_zeroshot.jsonl
4493951,the incidence of postoperative nausea and vomiting (PONV),H2 (haloperidol 2 mg),H0 (saline),binary,12.0,50.0,27.0,50.0,,,,,,,4493951_zeroshot.jsonl
4493951,the incidence of postoperative nausea and vomiting (PONV),H1(haloperidol 1 mg),H2 (haloperidol 2 mg),binary,14.0,49.0,12.0,50.0,,,,,,,4493951_zeroshot.jsonl
4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,and H2 (haloperidol 2 mg),H0 (saline),continuous,,50.0,,50.0,,,,,,,4493951_zeroshot.jsonl
4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,and H2 (haloperidol 2 mg),H1(haloperidol 1 mg),continuous,,50.0,,49.0,,,,,,,4493951_zeroshot.jsonl
4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,H0 (saline),"H1(haloperidol 1 mg),",continuous,,50.0,,49.0,,,,,,,4493951_zeroshot.jsonl
4511433,LDL cholesterol,5 mg elobixibat,placebo,continuous,,12.0,,12.0,4.78,0.65,4.29,0.71,,,4511433_zeroshot.jsonl
4511433,LDL cholesterol,2.5 mg,placebo,continuous,,12.0,,12.0,4.61,0.63,4.29,0.71,,,4511433_zeroshot.jsonl
4550271,Community knowledge,provider,control,binary,94.0,116.0,61.0,85.0,,,,,,,4550271_zeroshot.jsonl
4550271,Community knowledge,provider-school intervention,control,binary,97.0,115.0,61.0,85.0,,,,,,,4550271_zeroshot.jsonl
4550271,treatment according to guidelines,provider,control,binary,275.0,1832.0,299.0,1536.0,,,,,,,4550271_zeroshot.jsonl
4550271,treatment according to guidelines,provider-school intervention,control,binary,131.0,1496.0,299.0,1536.0,,,,,,,4550271_zeroshot.jsonl
4550271,the proportion of patients who tested positive and received (or were prescribed) an ACT,provider,control,binary,95.0,142.0,238.0,320.0,,,,,,,4550271_zeroshot.jsonl
4550271,the proportion of patients who tested positive and received (or were prescribed) an ACT,provider-school intervention,control,binary,59.0,98.0,238.0,320.0,,,,,,,4550271_zeroshot.jsonl
4574984,numbers overall complications,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",binary,238.0,326.0,241.0,326.0,,,,,,,4574984_zeroshot.jsonl
4574984,level of postoperative pain,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",binary,234.0,311.0,261.0,317.0,,,,,,,4574984_zeroshot.jsonl
4574984,overall mortality,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",binary,45.0,326.0,58.0,326.0,,,,,,,4574984_zeroshot.jsonl
4574984,Health-Related Quality of Life at 12 month - females,"intervention group, i.e. patient empowerment through information booklet and diary keeping - females","control group, which received standard care - females",continuous,,76.0,,71.0,61.07,,63.27,,,,4574984_zeroshot.jsonl
4574984,Health-Related Quality of Life at 12 month - males,"intervention group, i.e. patient empowerment through information booklet and diary keeping - males","control group, which received standard care - males",continuous,,151.0,,145.0,72.49,,71.71,,,,4574984_zeroshot.jsonl
4574984,postoperative in-hospital stay,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",continuous,,326.0,,326.0,,,,,,,4574984_zeroshot.jsonl
4675066,The mean cognitive score on the Bayley-III,iodine (150 μg/d),placebo,continuous,,27.0,,26.0,99.4,12.2,101.7,8.2,,,4675066_zeroshot.jsonl
4675066,The mean language score on the Bayley-III,iodine (150 μg/d),placebo,continuous,,27.0,,26.0,97.2,12.2,97.9,11.5,,,4675066_zeroshot.jsonl
4675066,The mean motor score on the Bayley-III,iodine (150 μg/d),placebo,continuous,,27.0,,26.0,93.9,10.8,92.4,9.7,,,4675066_zeroshot.jsonl
4678179,progression-free-survival (PFS),vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),continuous,,53.0,,53.0,4.0,,2.5,,,,4678179_zeroshot.jsonl
4678179,Median overall survival (OS),vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),continuous,,53.0,,53.0,6.9,,6.1,,,,4678179_zeroshot.jsonl
4678179,Response rates,vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),binary,4.0,53.0,7.0,53.0,,,,,,,4678179_zeroshot.jsonl
4678179,rate of adverse events,vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),binary,,53.0,,53.0,,,,,,,4678179_zeroshot.jsonl
4709985,would have liked more information on acupuncture,tertiary education,other educations,binary,,,,,,,,,,,4709985_zeroshot.jsonl
4830045,Birth status,Patients in the 3h group,Patients in the 20h group,binary,32.0,74.0,22.0,60.0,,,,,,,4830045_zeroshot.jsonl
4830045,Embryo quality,Patients in the 3h group,Patients in the 20h group,binary,524.0,672.0,503.0,700.0,,,,,,,4830045_zeroshot.jsonl
4879328,waist circumference,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,103.0,,112.0,-1.34,,-0.32,,,,4879328_zeroshot.jsonl
4879328,effects for walking,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104.0,,114.0,-0.55,,0.31,,,,4879328_zeroshot.jsonl
4879328,effects for vigorous activity,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,103.0,,114.0,0.2,,-0.4,,,,4879328_zeroshot.jsonl
4879328,FFBQ Total Index Score,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104.0,,114.0,0.07,,0.01,,,,4879328_zeroshot.jsonl
4879328,weekly moderate physical activity sessions,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,103.0,,114.0,0.19,,-0.68,,,,4879328_zeroshot.jsonl
4879328,accelerometer-assessed moderate to vigorous physical activity (MVPA),"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,99.0,,108.0,7.41,,-16.1,,,,4879328_zeroshot.jsonl
4879328,weight loss,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104.0,,114.0,-0.89,,0.3,,,,4879328_zeroshot.jsonl
4928400,Stone-free rate,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,binary,22.0,22.0,16.0,20.0,,,,,,,4928400_zeroshot.jsonl
4928400,Operative time,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22.0,,20.0,74.1,12.2,78.1,6.4,,,4928400_zeroshot.jsonl
4928400,Complication,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,binary,5.0,22.0,7.0,20.0,,,,,,,4928400_zeroshot.jsonl
4928400,Postoperative pain,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22.0,,20.0,6.4,1.3,5.1,1.6,,,4928400_zeroshot.jsonl
4928400,Hospital stay,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22.0,,20.0,4.2,1.2,2.1,1.1,,,4928400_zeroshot.jsonl
4928400,Time for return to daily activities,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22.0,,20.0,13.3,1.7,9.0,1.6,,,4928400_zeroshot.jsonl
4987981,FPG,metformin,placebo,continuous,,21.0,,23.0,15.2,19.2,2.2,10.0,,,4987981_zeroshot.jsonl
4987981,FPG,pioglitazone,placebo,continuous,,16.0,,23.0,20.5,17.4,2.2,10.0,,,4987981_zeroshot.jsonl
4987981,total cholesterol,metformin,placebo,continuous,,21.0,,23.0,21.8,25.2,1.4,29.2,,,4987981_zeroshot.jsonl
4987981,total cholesterol,pioglitazone,placebo,continuous,,16.0,,23.0,24.0,29.5,1.4,29.2,,,4987981_zeroshot.jsonl
4987981,triglycerides levels,metformin,placebo,continuous,,21.0,,23.0,44.3,45.4,1.1,43.3,,,4987981_zeroshot.jsonl
4987981,triglycerides levels,pioglitazone,placebo,continuous,,16.0,,23.0,53.3,36.9,1.1,43.3,,,4987981_zeroshot.jsonl
4987981,PASI,pioglitazone,placebo,continuous,,16.0,,23.0,3.9,,1.7,,,,4987981_zeroshot.jsonl
4987981,PASI,metformin,placebo,continuous,,21.0,,23.0,2.3,,1.7,,,,4987981_zeroshot.jsonl
4987981,ESI,pioglitazone,placebo,continuous,,16.0,,23.0,4.2,,2.3,,,,4987981_zeroshot.jsonl
4987981,ESI,metformin,placebo,continuous,,21.0,,23.0,1.3,,2.3,,,,4987981_zeroshot.jsonl
4987981,PGA,pioglitazone,placebo,continuous,,16.0,,23.0,2.3,,1.3,,,,4987981_zeroshot.jsonl
4987981,PGA,metformin,placebo,continuous,,21.0,,23.0,2.3,,1.3,,,,4987981_zeroshot.jsonl
4996097,"""a"" vowel improvement",Septoplasty,Control,continuous,,33.0,,30.0,,,,,,,4996097_zeroshot.jsonl
4996097,Total nasal resistance,Septoplasty,Control,continuous,,33.0,,30.0,0.25,,0.27,,,,4996097_zeroshot.jsonl
4996097,"""n"" consonant improvement",Septoplasty,Control,continuous,,33.0,,30.0,,,,,,,4996097_zeroshot.jsonl
5055753,The percentages of patients in the calm,0.2 mg oral clonidine,2 mg oral midazolam,binary,14.0,40.0,7.0,40.0,,,,,,,5055753_zeroshot.jsonl
5055753,The percentages of patients in the sedated scale,0.2 mg oral clonidine,2 mg oral midazolam,binary,17.0,40.0,7.0,40.0,,,,,,,5055753_zeroshot.jsonl
5055753,The mean ¬± SD of intraoperatively administered fentany,0.2 mg oral clonidine,2 mg oral midazolam,continuous,,40.0,,40.0,105.0,30.8,165.0,34.5,,,5055753_zeroshot.jsonl
5055753,the percentages of patients in the agitated sedation scale,0.2 mg oral clonidine,2 mg oral midazolam,binary,4.0,40.0,12.0,40.0,,,,,,,5055753_zeroshot.jsonl
5055753,the percentages of patients in the heavily sedated,0.2 mg oral clonidine,2 mg oral midazolam,binary,2.0,40.0,8.0,40.0,,,,,,,5055753_zeroshot.jsonl
5055753,Mean ± SD of heart rate at 60 min,0.2 mg oral clonidine,2 mg oral midazolam,continuous,,,,,,,,,,,5055753_zeroshot.jsonl
5056957,Weight reduction at 12 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,592.0,,459.0,55.91,12.51,56.48,12.6,,,5056957_zeroshot.jsonl
5056957,BMI reduction at 12 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,592.0,,459.0,21.07,3.96,21.27,3.76,,,5056957_zeroshot.jsonl
5056957,BMI z-score at 12months,Multi-component physical activity,Usual PE and sport programmes,continuous,,502.0,,406.0,0.61,1.11,0.66,1.13,,,5056957_zeroshot.jsonl
5056957,Weight reduction at 24 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,560.0,,425.0,61.08,12.72,61.94,13.23,,,5056957_zeroshot.jsonl
5056957,BMI reduction at 24 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,560.0,,425.0,21.86,4.06,22.06,4.33,,,5056957_zeroshot.jsonl
5056957,BMI z-score at 24 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,488.0,,343.0,0.69,1.12,0.71,1.09,,,5056957_zeroshot.jsonl
5062234,The visual analog scale scores at rest timepoint 24 h,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,continuous,,21.0,,21.0,2.0,,0.5,,,,5062234_zeroshot.jsonl
5062234,The visual analog scale score on coughing timepoint 24. h,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,continuous,,21.0,,21.0,4.0,,4.0,,,,5062234_zeroshot.jsonl
5062234,The 24 h morphine requirement,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,continuous,,21.0,,21.0,34.57,14.64,32.76,14.34,,,5062234_zeroshot.jsonl
5062234,intraoperative supplemental fentanyl,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,binary,8.0,21.0,16.0,21.0,,,,,,,5062234_zeroshot.jsonl
5079604,The restricted mean time to hyperglycemia relapse,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,continuous,,33.0,,15.0,480.0,,305.0,,,,5079604_zeroshot.jsonl
5079604,The probability of relapse,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,binary,9.0,33.0,11.0,15.0,,,,,,,5079604_zeroshot.jsonl
5079604,Disposition index (DI),subjects who remained in remission,patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si),continuous,,28.0,,20.0,2.0,,0.8,,,,5079604_zeroshot.jsonl
5079604,incremental area under the curve for insulin (AUCi),subjects who remained in remission,patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si),continuous,,28.0,,20.0,8000.0,,3000.0,,,,5079604_zeroshot.jsonl
5079604,hyperglycemia relapse-free survival,"metformin 1,000 mg daily",sitagliptin 100 mg daily,continuous,,17.0,,16.0,,,,,,,5079604_zeroshot.jsonl
5079604,Cox proportional hazards of failure-free survival,"metformin 1,000 mg daily",sitagliptin 100 mg daily,continuous,,17.0,,16.0,,,,,,,5079604_zeroshot.jsonl
5079604,Hyperglycemia relapse-free survival,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,continuous,,33.0,,15.0,,,,,,,5079604_zeroshot.jsonl
5079604,The 2-year failure rate,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,binary,13.0,33.0,12.0,15.0,,,,,,,5079604_zeroshot.jsonl
5086025,Intuitive eating total score,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26.0,,26.0,3.45,0.55,2.54,0.58,,,5086025_zeroshot.jsonl
5086025,Psychological flexibility,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26.0,,26.0,18.23,8.14,22.46,8.67,,,5086025_zeroshot.jsonl
5086025,General mental health,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26.0,,26.0,50.24,7.41,45.63,6.31,,,5086025_zeroshot.jsonl
5086025,Binge eating,Intuitive Eating and Acceptance and Commitment Therapy,Control,binary,7.0,26.0,14.0,26.0,,,,,,,5086025_zeroshot.jsonl
5086025,BMI,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26.0,,26.0,32.81,5.31,32.93,4.85,,,5086025_zeroshot.jsonl
5086025,General physical health,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26.0,,26.0,50.87,11.02,50.46,7.83,,,5086025_zeroshot.jsonl
5122613,Left SCTT,Digestion-resistant maltodextrin,Placebo,continuous,,29.0,,28.0,10.2,8.6,12.1,9.5,,,5122613_zeroshot.jsonl
5122613,Adverse events,Digestion-resistant maltodextrin,Placebo,binary,4.0,33.0,2.0,33.0,,,,,,,5122613_zeroshot.jsonl
5122613,Baseline characteristics and diet,Digestion-resistant maltodextrin,Placebo,continuous,,33.0,,33.0,10.0,4.6,11.5,4.6,,,5122613_zeroshot.jsonl
5122613,Improvement in faeces consistency,Digestion-resistant maltodextrin,Placebo,continuous,,33.0,,33.0,3.4,1.0,3.2,0.5,,,5122613_zeroshot.jsonl
5122613,Colonic transit time,Digestion-resistant maltodextrin,Placebo,continuous,,29.0,,28.0,39.7,22.3,48.0,25.0,,,5122613_zeroshot.jsonl
5154016,24 h drainage volume,Stypro hemostatic sponge,Gelatin sponge,continuous,,30.0,,32.0,187.9,82.0,230.8,75.0,,,5154016_zeroshot.jsonl
5154016,Second 24 h drainage volume,Stypro hemostatic sponge,Gelatin sponge,continuous,,30.0,,32.0,53.7,3.8,63.5,14.2,,,5154016_zeroshot.jsonl
5154016,Second 24 h drainage volume,Collagen hemostatic sponge,Gelatin sponge,continuous,,30.0,,32.0,63.3,8.9,63.5,14.2,,,5154016_zeroshot.jsonl
5154016,24 h drainage volume,Collagen hemostatic sponge,Gelatin sponge,continuous,,30.0,,32.0,185.2,68.0,230.8,75.0,,,5154016_zeroshot.jsonl
5154016,Total drainage volume,Stypro hemostatic sponge,Gelatin sponge,continuous,,30.0,,32.0,231.5,18.1,318.5,26.7,,,5154016_zeroshot.jsonl
5154016,Total drainage volume,Collagen hemostatic sponge,Gelatin sponge,continuous,,30.0,,32.0,248.5,18.8,318.5,26.7,,,5154016_zeroshot.jsonl
5244530,remission rate,person-centred general practitioners (GP) consultations,treatment as usual (TAU),binary,61.0,125.0,63.0,133.0,,,,,,,5244530_zeroshot.jsonl
5244530,sedative prescriptions,person-centred general practitioners (GP) consultations,treatment as usual (TAU),binary,52.0,125.0,51.0,133.0,,,,,,,5244530_zeroshot.jsonl
5244530,sick leave,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125.0,,133.0,124.8,102.5,123.3,85.0,,,5244530_zeroshot.jsonl
5244530,continued antidepressants until the 6-month,person-centred general practitioners (GP) consultations,treatment as usual (TAU),binary,86.0,125.0,78.0,133.0,,,,,,,5244530_zeroshot.jsonl
5244530,depression severity reduction 12 months,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125.0,,133.0,,,,,,,5244530_zeroshot.jsonl
5244530,change in quality of life 12 months,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125.0,,133.0,,,,,,,5244530_zeroshot.jsonl
5244530,psychological well-being,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125.0,,133.0,,,,,,,5244530_zeroshot.jsonl
5268424,score on the general dimension scale of negative affects (referred to as NA from here onward),view a video featuring individuals that live in extreme poverty,control,continuous,,55.0,,50.0,21.036,6.327,17.68,5.859,,,5268424_zeroshot.jsonl
5325897,First test results,Evaluation with feedback,Evaluation without feedback,continuous,,15.0,,15.0,10.24,0.77,9.73,0.77,,,5325897_zeroshot.jsonl
5325897,Second test results,Evaluation with feedback,Evaluation without feedback,continuous,,15.0,,15.0,17.73,0.46,12.13,0.47,,,5325897_zeroshot.jsonl
5325897,Final test results,Evaluation with feedback,Evaluation without feedback,continuous,,15.0,,15.0,18.53,0.22,18.99,0.22,,,5325897_zeroshot.jsonl
5360580,Plasma PlsPE,1 mg/day of Pls purified from scallop,placebo,continuous,,55.0,,48.0,0.16,,-0.34,,,,5360580_zeroshot.jsonl
5360580,occurrence of adverse events,1 mg/day of Pls purified from scallop,placebo,binary,,169.0,,167.0,,,,,,,5360580_zeroshot.jsonl
5360580,"WMS-R (30 min) In the patients aged 77 years or younger,",1 mg/day of Pls purified from scallop,placebo,continuous,,19.0,,21.0,1.84,,0.0,,,,5360580_zeroshot.jsonl
5360580,WMS-R (0 min),1 mg/day of Pls purified from scallop,placebo,continuous,,140.0,,135.0,1.41,,1.39,,,,5360580_zeroshot.jsonl
5380284,Pain scores 48 hours after the surgery,Gum-chewing group,No gum group,continuous,,38.0,,37.0,,,,,,,5380284_zeroshot.jsonl
5380284,Surgery duration,Gum-chewing group,No gum group,continuous,,38.0,,37.0,,,,,,,5380284_zeroshot.jsonl
5380284,Rates of POI,Gum-chewing group,No gum group,binary,2.0,38.0,2.0,37.0,,,,,,,5380284_zeroshot.jsonl
5380284,Consumption of fentanyl,Gum-chewing group,No gum group,continuous,,38.0,,37.0,1.01,0.29,1.0,0.37,,,5380284_zeroshot.jsonl
5380284,Pain scores 24 hours and 72 hours after the surgery,Gum-chewing group,No gum group,continuous,,38.0,,37.0,,,,,,,5380284_zeroshot.jsonl
5380326,Interferon gamma-induced protein 10,Vitamin D supplementation,Control,continuous,,40.0,,40.0,636.47,70.91,748.88,87.12,,,5380326_zeroshot.jsonl
5380326,Vitamin D levels,Vitamin D supplementation,Control,continuous,,40.0,,40.0,45.93,2.43,21.87,0.84,,,5380326_zeroshot.jsonl
5380326,Th1/Th2 cytokines,Vitamin D supplementation,Control,continuous,,40.0,,40.0,,,,,,,5380326_zeroshot.jsonl
5380326,Interleukin 2,Vitamin D supplementation,Control,continuous,,40.0,,40.0,4.49,2.11,28.69,16.29,,,5380326_zeroshot.jsonl
5380326,Dipeptidyl peptidase-4,Vitamin D supplementation,Control,continuous,,40.0,,40.0,6032.37,214.9,6408.33,288.11,,,5380326_zeroshot.jsonl
5380326,Tumor necrosis factor alpha,Vitamin D supplementation,Control,continuous,,40.0,,40.0,752.94,298.86,548.33,191.46,,,5380326_zeroshot.jsonl
5419060,Sample rejection rate: CHC A,Phlebotomy training programme,Control,binary,79.0,10218.0,60.0,7557.0,,,,,,,5419060_zeroshot.jsonl
5419060,Sample rejection rate: CHC B,Phlebotomy training programme,Control,binary,48.0,4114.0,45.0,3973.0,,,,,,,5419060_zeroshot.jsonl
5419060,Sample rejection rate: CDC C,Phlebotomy training programme,Control,binary,37.0,2279.0,38.0,2321.0,,,,,,,5419060_zeroshot.jsonl
5419060,Sample rejection rate: CDC D,Phlebotomy training programme,Control,binary,7.0,630.0,8.0,589.0,,,,,,,5419060_zeroshot.jsonl
5419060,Request-form errors: CHC A,Phlebotomy training programme,Control,binary,8.0,10218.0,11.0,7557.0,,,,,,,5419060_zeroshot.jsonl
5419060,Request-form errors: CHC B,Phlebotomy training programme,Control,binary,12.0,4114.0,11.0,3973.0,,,,,,,5419060_zeroshot.jsonl
5419060,Request-form errors: CDC C,Phlebotomy training programme,Control,binary,6.0,2279.0,3.0,2321.0,,,,,,,5419060_zeroshot.jsonl
5419060,Request-form errors: CDC D,Phlebotomy training programme,Control,binary,0.0,630.0,0.0,589.0,,,,,,,5419060_zeroshot.jsonl
5419060,Preanalytical errors: CHC A,Phlebotomy training programme,Control,binary,55.0,10218.0,47.0,7557.0,,,,,,,5419060_zeroshot.jsonl
5419060,Preanalytical errors: CHC B,Phlebotomy training programme,Control,binary,48.0,4114.0,45.0,3973.0,,,,,,,5419060_zeroshot.jsonl
5419060,Preanalytical errors: CDC C,Phlebotomy training programme,Control,binary,37.0,2279.0,38.0,2321.0,,,,,,,5419060_zeroshot.jsonl
5419060,Preanalytical errors: CDC D,Phlebotomy training programme,Control,binary,7.0,630.0,8.0,589.0,,,,,,,5419060_zeroshot.jsonl
5419060,Phlebotomy questionnaire score: CHC A,Phlebotomy training programme,Control,continuous,,5.0,,5.0,96.0,,63.0,,,,5419060_zeroshot.jsonl
5419060,Phlebotomy questionnaire score: CHC B,Phlebotomy training programme,Control,continuous,,7.0,,7.0,93.0,,58.0,,,,5419060_zeroshot.jsonl
5419060,Phlebotomy questionnaire score: CDC C,Phlebotomy training programme,Control,continuous,,7.0,,7.0,97.0,,60.0,,,,5419060_zeroshot.jsonl
5419060,Phlebotomy questionnaire score: CDC D,Phlebotomy training programme,Control,continuous,,4.0,,4.0,97.0,,63.0,,,,5419060_zeroshot.jsonl
5419060,Techinque related rejections: CHC A,Phlebotomy training programme,Control,binary,20.0,10218.0,20.0,7557.0,,,,,,,5419060_zeroshot.jsonl
5419060,Techinque related rejections: CHC B,Phlebotomy training programme,Control,binary,15.0,4114.0,8.0,3973.0,,,,,,,5419060_zeroshot.jsonl
5419060,Techinque related rejections: CDC C,Phlebotomy training programme,Control,binary,18.0,2279.0,15.0,2321.0,,,,,,,5419060_zeroshot.jsonl
5419060,Techinque related rejections: CDC D,Phlebotomy training programme,Control,binary,2.0,630.0,4.0,589.0,,,,,,,5419060_zeroshot.jsonl
5459456,number of days with received courses of antibiotics,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,continuous,,,,,,,,,,,5459456_zeroshot.jsonl
5459456,inflexion-extension for the C2-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,16.0,,8.0,6.25,0.9,6.5,0.9,,,5459456_zeroshot.jsonl
5459456,inflexion-extension for the C2-C4 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,16.0,,8.0,4.0,0.5,4.0,0.6,,,5459456_zeroshot.jsonl
5459456,inflexion-extension for the C4-C5 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,16.0,,8.0,1.45,0.3,1.3,0.2,,,5459456_zeroshot.jsonl
5459456,inflexion-extension for the C5-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,16.0,,8.0,1.35,0.15,1.4,0.2,,,5459456_zeroshot.jsonl
5459456,lateral bending for the C2-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,16.0,,8.0,9.15,1.2,9.6,1.1,,,5459456_zeroshot.jsonl
5459456,lateral bending for the C2-C4 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,16.0,,8.0,5.7,0.65,5.9,0.7,,,5459456_zeroshot.jsonl
5459456,lateral bending for the C4-C5 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,16.0,,8.0,2.0,0.35,1.8,0.2,,,5459456_zeroshot.jsonl
5459456,lateral bending for the C5-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,16.0,,8.0,2.05,0.35,2.0,0.3,,,5459456_zeroshot.jsonl
5459456,surgery time,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,16.0,,8.0,67.5,13.5,65.0,13.0,,,5459456_zeroshot.jsonl
5459456,blood loss,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,16.0,,8.0,55.5,18.5,51.0,20.0,,,5459456_zeroshot.jsonl
5459456,recovery time,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,16.0,,8.0,3.85,1.85,3.5,1.4,,,5459456_zeroshot.jsonl
5459456,time before eating,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,16.0,,8.0,4.5,2.0,3.9,2.3,,,5459456_zeroshot.jsonl
5459456,Flexion-Extension stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,16.0,,8.0,0.315,0.09,7.2,1.33,,,5459456_zeroshot.jsonl
5459456,Lateral bending stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,16.0,,8.0,0.05,0.015,2.53,0.67,,,5459456_zeroshot.jsonl
5459456,Rotation stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,16.0,,8.0,0.02,0.0,1.53,0.42,,,5459456_zeroshot.jsonl
5459456,new bone formation around the screws and bone-implant contact (BIC) in both sections,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating,ACVC,continuous,,8.0,,8.0,,,,,,,5459456_zeroshot.jsonl
547916,matrix metalloproteinase-9 (MMP-9),doxycycline (100 mg),placebo,continuous,,10.0,,4.0,2.18,1.94,3.26,3.58,,,547916_zeroshot.jsonl
5498715,Scores of external regulation,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,0.43,1.04,1.19,1.37,,,5498715_zeroshot.jsonl
5498715,Scores of amotivation,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,0.06,0.36,0.58,0.92,,,5498715_zeroshot.jsonl
5498715,Body mass index,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,25.32,3.05,26.59,3.53,,,5498715_zeroshot.jsonl
5498715,Sedentary behavior,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,4.26,1.76,5.91,2.21,,,5498715_zeroshot.jsonl
5498715,agility test,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,13.21,1.44,13.8,1.14,,,5498715_zeroshot.jsonl
5498715,Physical activity,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,854.0,271.6,470.0,80.46,,,5498715_zeroshot.jsonl
5498715,physical fitness - flexibility,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,35.53,5.87,26.83,5.47,,,5498715_zeroshot.jsonl
5498715,physical fitness - muscular endurance,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,17.83,2.7,12.48,2.9,,,5498715_zeroshot.jsonl
5498715,physical fitness - agility,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,13.21,1.44,13.8,1.14,,,5498715_zeroshot.jsonl
5498715,physical fitness - cardiorespiratory endurance,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,39.1,2.76,37.99,2.14,,,5498715_zeroshot.jsonl
5498715,Scores of intrinsic motivation,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,13.5,1.79,5.51,2.39,,,5498715_zeroshot.jsonl
5498715,Scores of perception of competence,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,17.2,3.46,14.1,3.82,,,5498715_zeroshot.jsonl
5498715,Scores of perception of autonomy,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,30.4,2.83,19.85,5.24,,,5498715_zeroshot.jsonl
5498715,Scores of enjoyment,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,30.0,3.83,24.89,5.2,,,5498715_zeroshot.jsonl
5498715,Scores of health care climate,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,30.0,,31.0,83.1,1.37,69.57,1.61,,,5498715_zeroshot.jsonl
5515881,memory score,demanding balance training program,relaxation group,continuous,,19.0,,21.0,9.44,5.48,8.0,4.16,,,5515881_zeroshot.jsonl
5515881,dynamic balance performance on the stability platform,demanding balance training program,relaxation group,continuous,,19.0,,21.0,7.54,2.57,6.29,1.84,,,5515881_zeroshot.jsonl
5515881,center of pressure (CoP) sway velocity,demanding balance training program,relaxation group,continuous,,19.0,,21.0,0.63,0.11,0.67,0.18,,,5515881_zeroshot.jsonl
5515881,spatial score,demanding balance training program,relaxation group,continuous,,19.0,,21.0,0.443,0.75,0.04,0.91,,,5515881_zeroshot.jsonl
5515881,VO2peak,demanding balance training program,relaxation group,continuous,,19.0,,21.0,32.07,6.52,31.947,7.89,,,5515881_zeroshot.jsonl
5534041,composite z-scores in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12.0,,12.0,0.11,0.81,-0.25,0.71,,,5534041_zeroshot.jsonl
5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12.0,,12.0,0.11,0.81,-0.25,0.71,,,5534041_zeroshot.jsonl
5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),continuous,,12.0,,12.0,0.11,0.81,0.13,0.82,,,5534041_zeroshot.jsonl
5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12.0,,12.0,0.13,0.82,-0.25,0.71,,,5534041_zeroshot.jsonl
5534041,composite z-scores in autism spectrum disorder (ASD),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12.0,,12.0,0.13,0.82,-0.25,0.71,,,5534041_zeroshot.jsonl
5539943,reflections of sustain talk,Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),continuous,,,,,,,,,,,5539943_zeroshot.jsonl
5539943,"""sustain talk"" (ST)",Language Enhanced Attention and Focus MI training condition (MI-LEAF),baseline,continuous,,,,,,,,,,,5539943_zeroshot.jsonl
5539943,"Frequency of client ""change talk"" (CT)",Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),continuous,,,,,,,,,,,5539943_zeroshot.jsonl
5539943,Motivational Interviewing (MI) knowledge,Language Enhanced Attention and Focus MI training condition (MI-LEAF),baseline,continuous,,,,,,,,,,,5539943_zeroshot.jsonl
5539943,Motivational Interviewing (MI) knowledge,MI training (MI-AU),baseline,continuous,,,,,,,,,,,5539943_zeroshot.jsonl
5539943,Motivational Interviewing (MI) knowledge,Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),continuous,,,,,,,,,,,5539943_zeroshot.jsonl
5541727,Tibial bone expansion,Allogeneic mesenchymal precursor cells,Control,continuous,,9.0,,5.0,0.5,2.4,4.0,2.3,,,5541727_zeroshot.jsonl
5541727,Treatment-related serious adverse events,Allogeneic mesenchymal precursor cells,Control,binary,0.0,11.0,0.0,6.0,,,,,,,5541727_zeroshot.jsonl
5541727,medial tibial cartilage volume loss,Allogeneic mesenchymal precursor cells,Control,continuous,,9.0,,5.0,0.7,5.9,-4.0,3.9,,,5541727_zeroshot.jsonl
5541727,lateral tibial cartilage volume loss,Allogeneic mesenchymal precursor cells,Control,continuous,,9.0,,5.0,-1.4,5.3,-2.7,4.4,,,5541727_zeroshot.jsonl
5541727,Activities of daily living,Allogeneic mesenchymal precursor cells,Control,continuous,,,,,,,,,,,5541727_zeroshot.jsonl
5541727,Symptoms,Allogeneic mesenchymal precursor cells,Control,continuous,,,,,,,,,,,5541727_zeroshot.jsonl
5541727,SF-36 bodily pain score,Allogeneic mesenchymal precursor cells,Control,continuous,,,,,,,,,,,5541727_zeroshot.jsonl
5559992,Anxiety,Buprenophine 32 mg,No treatment,continuous,,5.0,,,1.0,2.23,,,,,5559992_zeroshot.jsonl
5559992,Anxiety,Buprenophine 64 mg,No treatment,continuous,,4.0,,,1.25,2.5,,,,,5559992_zeroshot.jsonl
5559992,Anxiety,Buprenophine 96 mg,No treatment,continuous,,5.0,,,0.0,0.0,,,,,5559992_zeroshot.jsonl
5559992,Anxiety,Buprenophine 32 mg,Buprenophine 64 mg,continuous,,5.0,,4.0,1.0,2.23,1.25,2.5,,,5559992_zeroshot.jsonl
5559992,Anxiety,Buprenophine 32 mg,Buprenophine 96 mg,continuous,,5.0,,5.0,1.0,2.23,0.0,0.0,,,5559992_zeroshot.jsonl
5559992,Anxiety,Buprenophine 64 mg,Buprenophine 96 mg,continuous,,4.0,,5.0,1.25,2.5,0.0,0.0,,,5559992_zeroshot.jsonl
5571493,Glycemic level,Dw 5% with Quinine infusion,Dw 5% without Quinine infusion,continuous,,10.0,,10.0,82.0,5.0,92.0,7.0,,,5571493_zeroshot.jsonl
5571493,Glycemic level,Saline + Quinine infusion,Dw 5% + Quinine infusion,continuous,,10.0,,10.0,74.0,5.0,82.0,5.0,,,5571493_zeroshot.jsonl
5571493,Glycemic level,Saline + Quinine infusion,Saline without Quinine infusion,continuous,,10.0,,10.0,74.0,5.0,83.0,5.0,,,5571493_zeroshot.jsonl
5571493,QT interval,Saline + Quinine infusion,Saline without Quinine infusion,continuous,,,,,,,,,,,5571493_zeroshot.jsonl
5571493,QT interval,Dw 5%+ Quinine infusion,Dw 5% without Quinine infusion,continuous,,,,,,,,,,,5571493_zeroshot.jsonl
5571493,Hypoglycemia,Saline + Quinine infusion,Saline without Quinine infusion,binary,0.0,10.0,0.0,10.0,,,,,,,5571493_zeroshot.jsonl
5614421,The incidence of respiratory distress syndrome,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,42.0,402.0,41.0,388.0,,,,,,,5614421_zeroshot.jsonl
5614421,severity of any neonatal respiratory disease,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,,402.0,,388.0,,,,,,,5614421_zeroshot.jsonl
5614421,other respiratory morbidities,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,43.0,402.0,45.0,388.0,,,,,,,5614421_zeroshot.jsonl
5614421,"adverse infant outcomes, including serious infant composite outcome",vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,155.0,406.0,152.0,393.0,,,,,,,5614421_zeroshot.jsonl
5614421,side effects,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,134.0,394.0,118.0,382.0,,,,,,,5614421_zeroshot.jsonl
5617873,Parent-rated Aberrant Behavior Checklis improvement,Aripiprazole,Placbeo,continuous,,47.0,,45.0,-11.4,,-7.5,,,,5617873_zeroshot.jsonl
5617873,Clinician-rated Clinical Global Impression-Improvement scores,Aripiprazole,Placbeo,continuous,,47.0,,45.0,2.7,,3.4,,,,5617873_zeroshot.jsonl
5617873,Serious adverse effects,Aripiprazole,Placbeo,binary,0.0,47.0,1.0,45.0,,,,,,,5617873_zeroshot.jsonl
5617873,Inappropriate speech,Aripiprazole,Placbeo,continuous,,47.0,,45.0,-2.2,,-1.5,,,,5617873_zeroshot.jsonl
5617873,Social withdrawal,Aripiprazole,Placbeo,continuous,,47.0,,45.0,-5.2,,-4.7,,,,5617873_zeroshot.jsonl
5617873,Compulsion scale,Aripiprazole,Placbeo,continuous,,47.0,,45.0,-2.0,,-1.3,,,,5617873_zeroshot.jsonl
5655920,Nausea,Lixisenatide with normal renal function,Lixisenatide with mild impairment,binary,,,,,,,,,,,5655920_zeroshot.jsonl
5655920,vomiting,Lixisenatide with normal renal function,Lixisenatide with mild impairment,binary,,,,,,,,,,,5655920_zeroshot.jsonl
5655920,Nausea,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,binary,,,,,,,,,,,5655920_zeroshot.jsonl
5655920,vomiting,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,binary,,,,,,,,,,,5655920_zeroshot.jsonl
5655920,Nausea,Lixisenatide with moderate impairment,Lixisenatide with normal renal function,binary,,,,,,,,,,,5655920_zeroshot.jsonl
5655920,vomiting,Lixisenatide with moderate impairment,Lixisenatide with normal renal function,binary,,,,,,,,,,,5655920_zeroshot.jsonl
5655920,Hypoglycaemia,Lixisenatide with normal renal function,Lixisenatide with mild impairment,binary,,,,,,,,,,,5655920_zeroshot.jsonl
5655920,Hypoglycaemia,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,binary,,,,,,,,,,,5655920_zeroshot.jsonl
5686687,Pain,Resveratrol,Placebo,continuous,,22.0,,22.0,3.2,,3.9,,,,5686687_zeroshot.jsonl
5686687,Need for dipyrone,Resveratrol,Placebo,continuous,,5.0,,5.0,1944.0,1793.0,625.0,250.0,,,5686687_zeroshot.jsonl
5686687,Need for Ibuprofen,Resveratrol,Placebo,continuous,,5.0,,5.0,1200.0,848.0,5640.0,328.0,,,5686687_zeroshot.jsonl
5686687,Prolactin levels,Resveratrol,Placebo,continuous,,,,,,,,,,,5686687_zeroshot.jsonl
5686687,CA-125 levels,Resveratrol,Placebo,continuous,,,,,,,,,,,5686687_zeroshot.jsonl
5711682,In-stent late lumen loss at 9 months,Genoss drug-eluting stent (DES),Promus Element,continuous,,38.0,,39.0,0.11,0.25,0.16,0.43,,,5711682_zeroshot.jsonl
5711682,myocardial infarction (MI),Genoss drug-eluting stent (DES),Promus Element,binary,0.0,38.0,0.0,39.0,,,,,,,5711682_zeroshot.jsonl
5711682,target lesion revascularization (TLR),Genoss drug-eluting stent (DES),Promus Element,binary,1.0,38.0,1.0,39.0,,,,,,,5711682_zeroshot.jsonl
5711682,stent thrombosis,Genoss drug-eluting stent (DES),Promus Element,binary,0.0,38.0,0.0,39.0,,,,,,,5711682_zeroshot.jsonl
5711682,rates of death,Genoss drug-eluting stent (DES),Promus Element,binary,1.0,38.0,0.0,39.0,,,,,,,5711682_zeroshot.jsonl
5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),Duloxetine (D),continuous,,30.0,,30.0,137.06,61.3,91.7,35.5,,,5712123_zeroshot.jsonl
5712123,postoperative pain at rest,duloxetine 60 and etoricoxib 120mg (group D/E),placebo,continuous,,30.0,,30.0,2.0,,3.0,,,,5712123_zeroshot.jsonl
5712123,postoperative pain on movement,duloxetine 60 and etoricoxib 120mg (group D/E),placebo,continuous,,30.0,,30.0,3.0,,3.5,,,,5712123_zeroshot.jsonl
5712123,morphine requirements at 24 h,E group,P group,continuous,,30.0,,30.0,24.6,4.5,31.9,6.7,,,5712123_zeroshot.jsonl
5712123,morphine requirements at 24 h,D group,P group,continuous,,30.0,,30.0,22.6,4.1,31.9,6.7,,,5712123_zeroshot.jsonl
5712123,morphine requirements at 24 h,D/E group,P group,continuous,,30.0,,30.0,17.9,3.2,31.9,6.7,,,5712123_zeroshot.jsonl
5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),Placebo group (P),continuous,,30.0,,30.0,137.06,61.3,62.03,37.2,,,5712123_zeroshot.jsonl
5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),etoricoxib (E),continuous,,30.0,,30.0,137.06,61.3,105.3,28.4,,,5712123_zeroshot.jsonl
5726464,Glucose,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,89.0,,91.0,,,,5726464_zeroshot.jsonl
5726464,insulin,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,5.4,,5.8,,,,5726464_zeroshot.jsonl
5726464,25(OH)D levels,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,52.6,,27.0,,,,5726464_zeroshot.jsonl
5726464,Lipid profile: total cholesterol,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,174.0,,170.0,,,,5726464_zeroshot.jsonl
5726464,Lipid profile: HDL-c,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,51.0,,50.0,,,,5726464_zeroshot.jsonl
5726464,Lipid profile: LDL-c,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,97.0,,93.0,,,,5726464_zeroshot.jsonl
5726464,Lipid profile: Triglycerides,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,102.0,,100.0,,,,5726464_zeroshot.jsonl
5726464,Changes in body mass index,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,25.1,,24.1,,,,5726464_zeroshot.jsonl
5726464,Metabolic syndrome,Vitamin D plus calcium supplementation,Placebo,binary,9.0,66.0,11.0,75.0,,,,,,,5726464_zeroshot.jsonl
5771543,CGI-I response rate,fluoxetine,placebo,binary,79.0,101.0,62.0,99.0,,,,,,,5771543_zeroshot.jsonl
5771543,CGI-I response rate,desvenlafaxine,placebo,binary,68.0,99.0,62.0,99.0,,,,,,,5771543_zeroshot.jsonl
5771543,Treatment-emergent adverse events (TEAEs),desvenlafaxine,placebo,binary,69.0,115.0,79.0,112.0,,,,,,,5771543_zeroshot.jsonl
5771543,Treatment-emergent adverse events (TEAEs),fluoxetine,placebo,binary,72.0,112.0,79.0,112.0,,,,,,,5771543_zeroshot.jsonl
5773985,mean volume of both the solutions used,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,4.15,0.52,4.12,0.6,,,5773985_zeroshot.jsonl
5773985,subjective onset of action,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,3.0,1.08,2.92,1.03,,,5773985_zeroshot.jsonl
5773985,objective onset of action,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,7.28,1.59,7.4,1.93,,,5773985_zeroshot.jsonl
5773985,duration of surgical procedure,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,32.2,15.5,33.68,18.91,,,5773985_zeroshot.jsonl
5773985,the mean duration of postoperative analgesia,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,508.92,63.3,1840.84,819.51,,,5773985_zeroshot.jsonl
5773985,number of analgesic tablets,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,1.64,0.99,0.8,1.08,,,5773985_zeroshot.jsonl
57750,Death or myocardial infarction,eptifibatide,placebo,binary,14.2,,15.7,,,,,,,,57750_zeroshot.jsonl
57750,Myocardial infarction,eptifibatide,placebo,binary,12.6,,13.6,,,,,,,,57750_zeroshot.jsonl
5777419,the total cultivable microbiota,probiotic,placebo,continuous,,16.0,,15.0,0.8,,0.5,,,,5777419_zeroshot.jsonl
5777419,the total cultivable microbiota,antibiotic,placebo,continuous,,16.0,,15.0,1.9,,0.5,,,,5777419_zeroshot.jsonl
5777419,attachment gain,probiotic,placebo,continuous,,16.0,,15.0,-0.4,,-0.4,,,,5777419_zeroshot.jsonl
5777419,reduction of PPD,probiotic,placebo,continuous,,16.0,,15.0,-0.5,,-0.6,,,,5777419_zeroshot.jsonl
5777419,reduction of plaque,probiotic,placebo,continuous,,16.0,,15.0,-26.4,,-28.7,,,,5777419_zeroshot.jsonl
5777419,attachment gain,antibiotic,placebo,continuous,,16.0,,15.0,-0.5,,-0.4,,,,5777419_zeroshot.jsonl
5777419,reduction of PPD,antibiotic,placebo,continuous,,16.0,,15.0,-0.6,,-0.6,,,,5777419_zeroshot.jsonl
5777419,reduction of plaque,antibiotic,placebo,continuous,,16.0,,15.0,-26.8,,-28.7,,,,5777419_zeroshot.jsonl
5777645,HbA1c levels,to peer-led structured patient education,conventional care alone,continuous,,70.0,,70.0,-1.05,2.0,-0.15,1.7,,,5777645_zeroshot.jsonl
5777645,Mean BMI change,to peer-led structured patient education,conventional care alone,continuous,,70.0,,70.0,-1.65,2.5,0.05,3.2,,,5777645_zeroshot.jsonl
5777645,Mean waist circumference,to peer-led structured patient education,conventional care alone,continuous,,70.0,,70.0,-3.34,9.3,2.65,10.3,,,5777645_zeroshot.jsonl
5781260,adverse events,lemon verbena extract,placebo,binary,,22.0,,22.0,,,,,,,5781260_zeroshot.jsonl
5781260,Movement induced pain (VAS),lemon verbena extract,placebo,continuous,,17.0,,20.0,,,,,,,5781260_zeroshot.jsonl
5781260,Interleukin 6,lemon verbena extract,placebo,continuous,,17.0,,20.0,,,,,,,5781260_zeroshot.jsonl
5781260,Exercise-induced Creatine kinase (CK),lemon verbena extract,placebo,continuous,,17.0,,20.0,,,,,,,5781260_zeroshot.jsonl
5781260,exercise-related loss of muscle strength (MVC),lemon verbena extract,placebo,continuous,,17.0,,20.0,,,,,,,5781260_zeroshot.jsonl
5781260,Glutathione peroxidase (GPxP),lemon verbena extract,placebo,continuous,,17.0,,20.0,,,,,,,5781260_zeroshot.jsonl
5800236,Months of sick leave,Nacadia® nature-based therapy,Cognitive behavioral therapy,continuous,,,,,,,,,,,5800236_zeroshot.jsonl
5830087,objective response rate (ORR),"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),binary,29.0,48.0,10.0,23.0,,,,,,,5830087_zeroshot.jsonl
5830087,disease control rate,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),binary,45.0,48.0,21.0,23.0,,,,,,,5830087_zeroshot.jsonl
5830087,duration of objective response,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),continuous,,29.0,,10.0,10.3,,5.6,,,,5830087_zeroshot.jsonl
5830087,progression-free survival,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),continuous,,50.0,,23.0,11.6,,9.6,,,,5830087_zeroshot.jsonl
5874317,Knee extension (1-rep Max),Bilateral training,Unilateral training,continuous,,9.0,,9.0,237.2,51.0,182.4,8.4,,,5874317_zeroshot.jsonl
5874317,Knee flexion (1-rep Max),Bilateral training,Unilateral training,continuous,,9.0,,9.0,99.8,10.2,86.8,2.9,,,5874317_zeroshot.jsonl
5874317,Change of direction improvement,Bilateral training,Unilateral training,continuous,,9.0,,9.0,5.46,0.2,5.67,0.16,,,5874317_zeroshot.jsonl
5874317,Squat jump,Bilateral training,Unilateral training,continuous,,9.0,,9.0,0.37,0.04,0.34,0.04,,,5874317_zeroshot.jsonl
5874317,Horizontal countermovement jump,Bilateral training,Unilateral training,continuous,,9.0,,9.0,2.34,0.07,2.21,0.15,,,5874317_zeroshot.jsonl
5874317,Horizontal triple jump (non-dominant leg),Bilateral training,Unilateral training,continuous,,9.0,,9.0,6.29,0.31,6.35,0.34,,,5874317_zeroshot.jsonl
5884950,objective-SCORAD score,extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,continuous,,13.0,,13.0,13.0,,17.0,,,,5884950_zeroshot.jsonl
5884950,chemokines CXCL9,extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,continuous,,21.0,,20.0,2.33,,1.95,,,,5884950_zeroshot.jsonl
5971365,clinically meaningful improvement at week 144 (⩾3-point increase on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,binary,188.0,287.0,144.0,277.0,,,,,,,5971365_zeroshot.jsonl
5971365,Symbol Digit Modalities Test (SDMT) score at week 144 in limited patients,daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,continuous,,287.0,,277.0,6.3,12.6,3.1,13.2,,,5971365_zeroshot.jsonl
5971365,Symbol Digit Modalities Test (SDMT) score at week 96,daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,continuous,,720.0,,682.0,4.1,12.4,2.9,12.7,,,5971365_zeroshot.jsonl
5971365,clinically meaningful worsening at week 96 (⩾3-point decrease on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,binary,140.0,720.0,169.0,682.0,,,,,,,5971365_zeroshot.jsonl
5971365,clinically meaningful improvement at week 96 (⩾3-point increase on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,binary,432.0,720.0,369.0,682.0,,,,,,,5971365_zeroshot.jsonl
5976307,induction time,etomidate,propofol based on midazolam,continuous,,62.0,,62.0,2.46,0.993,2.21,1.0,,,5976307_zeroshot.jsonl
5976307,total procedure time,etomidate,propofol based on midazolam,continuous,,62.0,,62.0,29.73,12.23,29.46,16.04,,,5976307_zeroshot.jsonl
5976307,awake time,etomidate,propofol based on midazolam,continuous,,62.0,,62.0,15.08,10.06,17.07,11.83,,,5976307_zeroshot.jsonl
5976307,The incidence rate of all cardiopulmonary adverse events,etomidate,propofol based on midazolam,binary,34.0,62.0,45.0,62.0,,,,,,,5976307_zeroshot.jsonl
5976307,The incidence rate of vital sign fluctuation (VSF),etomidate,propofol based on midazolam,binary,17.0,62.0,31.0,62.0,,,,,,,5976307_zeroshot.jsonl
5976307,the incidence rate of adverse events disturbing the procedure,etomidate,propofol based on midazolam,binary,16.0,62.0,5.0,62.0,,,,,,,5976307_zeroshot.jsonl
5976307,The incidence rate of myoclonus,etomidate,propofol based on midazolam,binary,10.0,62.0,1.0,62.0,,,,,,,5976307_zeroshot.jsonl
5976949,ANGPTL4 expression,"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)",control group- normal glucose tolerance,continuous,,20.0,,25.0,23.1,25.6,98.3,104.6,,,5976949_zeroshot.jsonl
5976949,ANGPTL4 expression,"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)","GDM2 (less tight glycaemic targets, <5.3_mmol/L and <_7.8_mmol/L)",continuous,,20.0,,21.0,23.1,25.6,21.5,25.8,,,5976949_zeroshot.jsonl
5976949,leptin/adiponectin ratio (LAR),"GDM2 (less tight glycaemic targets, <5.3 mmol/L and < 7.8 mmol/L)","GDM1 (tight glycaemic targets, fasting blood glucose_<_5.1_mmol/L and <7.0_mmol/L postprandial) postprandial,), control group- normal glucose tolerance)",continuous,,21.0,,20.0,1.7,1.66,0.97,1.31,,,5976949_zeroshot.jsonl
5976949,leptin/adiponectin ratio (LAR),"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)",control group- normal glucose tolerance,continuous,,20.0,,25.0,0.97,1.31,0.72,0.46,,,5976949_zeroshot.jsonl
